We
Create
Innovations
for the
WORLD
2013 –2014
All For
Creativity
Always striving
to take the
road less traveled
For better health
worldwide
Disease and health have no national boundaries and
Otsuka’s line of thought about how to tackle unaddressed
medical needs also takes us far beyond the boundaries
of conventional thinking. One of our internal golden rules is
‘All For Creativity.’ We operationalize this by focusing
exclusively on products that only Otsuka can imagine and
avoiding fast-follower products or copycat generic drugs.
It has been 42 years since Otsuka Pharmaceutical established
its first research institute for therapeutic drugs in 1971. Today,
the company’s researchers are persevering with drug discovery
research into much-awaited treatments for difficult diseases
that affect people around the world.
Building on its blockbuster antipsychotic drug ABILIFY, which
took 25 years to research and develop and is now available
in 60 countries and regions, in 2013 Otsuka Pharmaceutical
launched Abilify Maintena in the U.S. This new product, a oncemonthly, extended-release injection, provides a new treatment
to help prevent relapse in patients with schizophrenia, a choice
for patients who have difficulty taking pills every day.
Tuberculosis is a global public health problem, well-suited to
Otsuka’s research on antimicrobial agents underway since the
research institute was established, as well as our passion to take
on big challenges. Otsuka Pharmaceutical has been grappling with
this difficult disease for over 30 years, aiming to develop a drug
for difficult-to-treat, multidrug-resistant tuberculosis.
The company is also working on the development of a treatment
for autosomal dominant polycystic kidney disease (ADPKD),
a genetic disease for which there is currently no treatment.
Ever since our chairman Akihiko Otsuka established the research
institute for in-house development of therapeutic drugs, Otsuka
Pharmaceutical’s researchers have continued to embrace their
mission with high aspirations, great passion, and steadfast
dedication. All of their efforts reflect their commitment to patients.
World-class
or
Not at All
Firmly Rooted in Tokushima,
Not Tokyo
in Japan is always saying, ‘Tokyo, Tokyo.’ We like to go against the
‘‘ Everyone
grain. Tokyo is all well and good, but because all the companies there are
It has been nearly 50 years since Otsuka Pharmaceutical
was established in Tokushima in 1964.
swimming in the same pool of information, ultimately, they all end up making
the same products. Outlying areas lack convenience, but they give you more
room to ponder things. One advantage to Tokushima is that the university has
both a faculty of pharmaceutical sciences and a faculty of medicine. Right now
we are investing in bringing more people and facilities to Tokushima. To better
communicate our Tokushima hometown flavor, we have staff who carefully
explain our business and community engagement to visitors from abroad. We
have even built a children’s nursery at our factory site.
Even today, the company carefully nurtures creativity
in Tokushima on the southern Japanese island of Shikoku,
far from the bright lights of the big city.
Because living in rural areas requires resourcefulness, I always maintained the
view that we had to take the hard way. This really challenges people; also, there
is less competition when you take the hard way, the road less traveled.
Some of the U.S. and European drug makers are located in smaller towns
and their employees also work diligently while contributing to their local
communities. There aren’t really any problems with locations like these. We can
exercise ingenuity and recruit talented people. If we can attract personnel and
funds, I think it is preferable to be in an outlying area. My thinking may be a
bit contrarian, but I think that’s just fine.
‘‘
Akihiko Otsuka, the champion
of drug discovery research
(photo taken when he was the
Tokushima Factory Manager)
2 3
Interview with Akihiko Otsuka,
Chairman of Otsuka Holdings,
in Hitto no Keiei-Gaku, Nikkei Publishing Inc.
Taro Iwamoto
Akihiko Otsuka
President,
Representative Director
Chairman
Dreams Are the Energy of
Otsuka Pharmaceutical
Otsuka Pharmaceutical Is
a Big Venture Company
Rather Than a Big Pharma Company
Otsuka Pharmaceutical Is Engaged
in Overall Healthcare
In 2010, Otsuka Pharmaceutical Co.,
Ltd., which started as a small company in Tokushima, listed on the First
Section of the Tokyo Stock Exchange.
Both the scale of our business and
our product line have grown;
with Otsuka Pharmaceutical products
available to the people of 81 countries
around the world and consolidated
revenues of more than USD 12 billion*
(in fiscal 2012), we have become a
large company. But our true nature
has not changed from our days
as a small company: Otsuka Pharmaceutical continues to nurture
the spirit of creativity, curiosity,
and perseverance.
Looking at examples of major corporations, we can see that mainstream
ways of thinking and established
approaches are quickly becoming
obsolete in a rapidly changing business environment. However, innovation cannot come from bureaucracies
or organizations, but from candid,
passionate individuals who convert
ideas into tangible products.
At Otsuka Pharmaceutical, we are
committed to the overall health and
well-being of people. To accomplish
this goal, we have identified four
business segments on a global scale:
‘Pharmaceuticals’ based on prescription drugs to make people well
again; ‘Nutraceuticals’ based on the
concept of nutritional foods and
beverages that contribute to wellness;
‘Cosmedics’ for skin care; and
‘Soylution,’ based on the solutions
soy can provide to human health
and environmental issues. Contributing to the health and quality of life
of people around the world is our
aspiration and our dream.
Children have dreams. People at
Otsuka view the world with a childlike
gaze, aiming to achieve their dreams
together with their colleagues. Our
people persevered with an idea that
most others ignored, succeeding in
commercializing it into an innovative
medication 20 years later. We have
researchers who followed their passion and visited hospitals on the other
side of the globe, seeking dialogues
with patients. We are proud to have
colleagues who hold on to their
dreams and passions, bringing them
into our innovation process.
Otsuka Pharmaceutical is a big
venture company. Brimming with a
youthful spirit of innovation, we keep
challenging accepted opinions and
ideas. We welcome change in the
business environment as an opportunity and attract colleagues who are
not afraid of changing dynamics.
Otsuka Pharmaceutical will continue
to deliver innovative products to
contribute to global human health and
well-being.
Taro Iwamoto
* 1 USD = 79.80 yen
Hiroshi Inaka
Tatsuro Watanabe
Yoichi Yabuuchi
Susumu Tamai
Hiroshi Ishikawa
Tatsuo Higuchi
Tetsuro Kikuchi
Senior Managing Director,
General Manager,
Production Headquarters
Managing Director
(Human Resources and
Legal Affairs)
Executive Fellow,
Research
Executive Director,
Executive Operating Offi cer,
Pharmaceutical Marketing
Headquarters
Fellow,
Medicinal Chemistry
Executive
Director
Fellow, Qs’ Research Institute,
Director
as of June 6, 2013
4 5
Taro Iwamoto
Akihiko Otsuka
Masayuki Umeno
President,
Representative Director
Chairman
Vice President,
Representative Director
Hiroyoshi Umehara
Yasuhisa Katsuta
Hiroshi Sugawara
Standing Audit &
Supervisory Board Member
Audit & Supervisory
Board Member
Audit & Supervisory
Board Member
Business
Overview
Pharmaceutical Business
Providing New Drugs to Help Patients Worldwide Recover
from Disease as Quickly as Possible
At Otsuka Pharmaceutical,
we are committed to a holistic
approach to human health and
well-being and are striving to
create innovative, thoroughly
original products based on our
corporate philosophy:
Otsuka Pharmaceutical is dedicated
to the research & development
of highly-innovative drugs and
diagnostics. Leveraging our research
culture of curiosity, determination
and unconventional thinking, we
strive for solutions that only Otsuka
can deliver to improve the health
of people across the world.
Japan, grew strongly upon the
authorized start date of long-term
prescribing that occurs after new
drug launches. In February 2013,
Neupro Patch, the world’s first
transdermal dopamine agonist, was
launched for the first time in Japan
for both Parkinson’s disease and
restless legs syndrome.
Our R&D philosophy places emphasis on encouraging individual
researchers to take the untraveled
path, pursuing fresh ideas within
a collaborative, accommodating
environment. Supported by the
global integration of our research
and development institutes in Asia,
the U.S. and Europe, the result
has been epoch-making drugs in
the following fields.
Cardiovascular: The vasopressin V2
receptor antagonist Samsca, which
is now available in 14 countries and
regions, has achieved good penetration in medical settings thanks to the
new value and utility it provides as
an oral aquaretic drug.
Pharmaceutical Business Division
Oncology: The anticancer agent
SPRYCEL, for which Otsuka Pharmaceutical has an alliance with BMS 3 in
Japan, the U.S., and Europe, continued to record strong growth globally
after it received approval as a firstline treatment for chronic myelogenous leukemia (CML). Busulfex,
the only drug approved by the U.S.
Food and Drug Administration (FDA)
for the conditioning regimen prior
to hematopoietic progenitor cell
transplantation, is now available in
over 50 countries through Otsuka
Pharmaceutical and its partners.
It has become a standard treatment
replacing radiotherapy within
the bone marrow transplantation
regimen. As of April 2013, Otsuka
Pharmaceutical is independently
developing the Busulfex business in
Japan and Asia, building on its track
record in the U.S. and Canada.
Central Nervous System (CNS): The
antipsychotic drug ABILIFY, which
is available in 60 countries and
regions, has reached 7th place 1 in
the global ranking of drug sales. In
the U.S., growing prescriptions for
bipolar disorder and as an adjuvant
therapy for major depression pushed
ABILIFY to the top sales position 2
among prescription drugs. On April
1, 2013, Otsuka began co-promotion
of ABILIFY in Europe with Lundbeck.
In Japan, the additional indication of
adjunctive therapy for major depressive disorder has been granted.
Diagnostic Division
Nutraceuticals Division
Otsuka International
Asia / Arab (OIAA) Division
* Otsuka International Asia Arab
Marketing of Abilify Maintena,
a once-monthly extended-release
injection, began in the U.S. in March
2013 as a new treatment option for
schizophrenia, building on the
success of ABILIFY. In December
2012, a new drug application was
submitted to the European Medicines Agency (EMA), and in September 2013, an advisory committee to
the EMA issued a positive opinion
that recommended approval.
Sales of the antiepileptic drug
E Keppra, which Otsuka Pharmaceutical is co-promoting with UCB in
Corporate
Profile
Financial
Performance
Company Name:
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Reports
Growth in Sales and Income
for Three Straight Years:
Share of Business Outside Japan
Reaches 62%
Head Office:
2-9, Kanda Tsukasa-machi,
Chiyoda-ku,
Tokyo 101-8535, Japan
Mucous Membranes: The antigastritis and anti-gastric ulcer agent
Mucosta, which protects and improves the gastric mucosa, is the
4th-most prescribed drug in Japan.4
In the field of ophthalmology, longterm prescriptions are now available
for Mucosta ophthalmic suspension
UD2%, a dry eye treatment that repairs the mucous membrane of the
eye and promotes mucin production.
Osaka Headquarters:
3-2-27, Otedori, Chuo-ku,
Osaka 540-0021, Japan
FY 2012
FY 2011
FY 2010
FY 2009
FY 2008
$ 10.1
$ 9.6
$ 9.3
1
©2013 IMS Health World Review
Estimated based on ‘Preview2013 (Year 2012
Sales Data)’
Reprinted with permission
2
Top sales out of all drugs in the U.S. from
October to December 2012 and again from
January to March 2013.
©2013 IMS Health MIDAS Quantum 1Q/2013
Estimated based on ‘Sales data’
Reprinted with permission
3
Bristol-Myers Squibb
4
© 2013 IMS JAPAN K.K.
Estimated based on ‘MDI2012 ’
Reprinted with permission
5
Based on US News & World Report Pharmacy Times Survey
6
Pharmavite calculation based in part on data
reported by Nielsen through its Scantrack ®
service for the Dietary Supplements category
in dollar and unit sales, for the 52-week
period ending 12/29/2007 and 12/28/2008 in
US Food Drug Mass channels; and for the 52week period ending 12/26/2009, 12/25/2010,
12/24/2011 and 12/22/2012 in US xAOC
channels. ©2013 The Nielsen Company
7
Cosmedics:
cosmetics + medicine
79.80 yen
79.79 yen
87.79 yen
92.10 yen
91.03 yen
FY 2012
FY 2011
FY 2010
FY 2009
FY 2008
Operating income
$ 1,086
$ 825
$ 883
Net sales
Ph 74.9 % / NC 25.1%
D 38.0 % / O 62.0 %
Ph 73.0 % / NC 27.0 %
D 38.4 % / O 61.6 %
Ph 71.7 % / NC 28.3 %
D 39.8 % / O 60.2%
Ph 69.2 % / NC 30.8 %
D 42.7 % / O 57.3 %
Pharmaceuticals / Nutraceuticals
Domestic / Overseas
FY 2012
FY 2011
FY 2010
FY 2009
Ph 68.6 % / NC 31.4 %
6 7
D 54.3 % / O 45.7%
as of March 3, 2013
FY 2008
28,000
(approximate number of
employees of
Otsuka Pharmaceutical affiliates
around the world)
Cosmedics 7 : In our Cosmedics
business for healthy skin, Otsuka
Pharmaceutical launched an SPF50
sunscreen in the UL•OS brand of
men’s skincare products in February
2013. UL•OS is expanding steadily
as a familiar skincare brand for the
whole body. Sales of InnerSignal,
a skincare line for women, doubled
after moving to a mail-order model.
$ 1,732 million
$ 11.4
President:
Taro Iwamoto
1 USD =
1 USD =
1 USD =
1 USD =
1 USD =
Vitamins, minerals and supplements: The U.S. brand Nature Made
has been named the number-one,
pharmacist-recommended brand in
eight categories.5 Nature Made has
also been a favorite with consumers
as the number-one national vitamin
brand sold in the U.S. for six consecutive years.6 In 2013, Nature Made
strengthened its supply system with
the construction of a new production site in the state of Alabama. In
Japan, sales of Super Vitamin D,
launched in October 2012, are growing steadily.
$ 1,504
$ 12.1 billion
Established:
August 10, 1964
Employees:
5,652
Soylution: Otsuka Pharmaceutical
has been focusing on developing
new soy products and creating new
customers based on the concept of
‘Soylution’ – that soy can provide
solutions to human health and environmental issues. In April 2012, the
company launched the healthy soy
snack SoyCarat. Along with the soy
bar SOYJOY, which is now available
in 11 countries and regions, and
the sparkling soy water SOYSH, the
company now has a lineup of three
Soylution products. In April 2013,
the company also launched the new
SOYJOY Peanuts in Japan.
Foreign currency-denominated sales
were converted to yen based on the
exchange rate on the last day of the year
for figures through fi scal 2009 and on
the average annual rate for fi scal 2010
and later.
Tokushima Headquarters:
463-10, Kagasuno, Kawauchi-cho,
Tokushima 771-0192, Japan
Capital:
20 billion yen
Rehydration: The water and
electrolyte supplement drink
POCARI SWEAT is now available
in 17 countries and regions, with
Vietnam most recently added in
2012. Demand is especially strong
in Indonesia. In Japan, in April
2013 the company launched
POCARI SWEAT ION WATER, which
is suited to modern lifestyles with
fewer calories, a light sweetness,
and a refreshing aftertaste. In this
way, POCARI SWEAT is still creating
new markets as a rehydration beverage for everyday use, not just after
actively perspiring.
Since fi scal 2010, the company has
calculated consolidated figures for
Otsuka Pharmaceutical and its affiliates.
Consolidated figures have not
been audited.
Otsuka Pharmaceutical is a
total healthcare company dedicated
to two core businesses:
pharmaceuticals and nutraceuticals.
In fiscal 2012, the company achieved
growth in sales and income for
the third consecutive year, with total
sales for Otsuka Pharmaceutical
and its affiliates about USD 12 billion
and operating income exceeding
USD 1.7 billion.
Tokyo Headquarters:
Shinagawa Grand Central Tower
2-16-4, Konan, Minato-ku,
Tokyo 108-8242, Japan
Nutrition & Sante SAS (N&S):
N&S, which has a presence in more
than 40 countries mainly in Europe,
acquired a gluten-free nutrition
company from Lactalis Group, a
multinational dairy conglomerate, in
December 2012. In Japan, two N&S
brands, Gerblé and Gerlinéa, are
growing steadily.
Otsuka Pharmaceutical develops
and delivers innovative products,
based on cutting-edge science, to
maintain and promote people’s
health around the world. Our
nutraceutical business has defined
and cultivated totally new market
segments by communicating the
unique value of its products to
consumers in person. Here is an
overview of recent progress
by segment.
We keep g r o w i n g
Divisions
Nutraceutical Business
Creating Unprecedented Products That Help People
Worldwide to Enjoy Healthier, More Active Lives
more information
www.otsuka.co.jp/en/product/
Driving on Two Wheels
Nutraceutical Business
Pharmaceutical Business
Pharmaceutical products
Nutraceutical Business products
Antipsychotic
POCARI SWEAT
POCARI SWEAT ION WATER
ABILIFY
Antipsychotic
ORONAMIN C DRINK
ORONAMIN C ROYALPOLIS
Abilify Maintena
V2-receptor antagonist
Samsca
Calorie Mate
Calorie Mate BLOCK
Calorie Mate JELLY
V2-receptor antagonist
Physuline
Antiepileptic drug
Nature Made
NATURE’S RESOURCE
E Keppra 1
ABILIFY
Transdermal Dopamin Agonist
Gerblé
Gerlinéa
Neupro Patch
Antiplatelet agent
Pletaal
POCARI SWEAT
ION WATER
POCARI SWEAT
Anti-gastritis & anti-gastric ulcer agent
Mucosta
Conditioning agent prior to allogenic
hematopoietic progenitor cell transplantation
Amino-Value 4000
Amino-Value CONC.
Amino-Value SUPPLEMENT STYLE
Busulfex
Anti-cancer
Abilify Maintena
SPRYCEL 2
energen
energen FAST BREAK jelly
Bronchodilator
Meptin (for oral administration)
Bronchodilator
Meptin (for inhalation)
Jog Mate Protein Jelly
Calorie Mate
METROMINT
Bronchodilator
E Keppra
UNIPHYL LA
theCALCIUM
Levocarnitine preparation
The Wise Man’s Dining
Double Support
L- Cartin
Oral nutrient for liver failure
Omugi Seikatsu
Aminoleban EN powder mix
Business
alliances in
Japan
FIBE-MINI
FIBE-MINI PLUS
FIBE-MINI JELLY
Sustained-release ß-blocker
Mikelan LA
ß-blocker
1
Mikelan
Co-promotion with
UCB Japan Co., Ltd.
Hyperlipidemia agent
Lorelco
2
Neupro Patch
Co-promotion with
Bristol-Myers K.K.
Hyperlipidemia agent, climacteric disturbance
and irritable bowel syndrome
FIBE-MINI
ORONAMIN C
DRINK
AminoValue 4000
Hi-z
Therapeutic agent for dry eye
3
Co-marketing with
Senju Pharmaceutical
Co., Ltd. (developed
by Otsuka
Pharmaceutical)
Soylution
ß-blocker ophthalmic solution
SOYJOY
SOYSH
SoyCarat
Mikelan LA ophthalmic solution 3
ß-blocker ophthalmic solution
Mikelan ophthalmic solution 3
4
Licensed by
Toyama Chemical
Co., Ltd.
Mucosta ophthalmic suspension
Nature Made
Broad-spectrum antibacterial
ophthalmic solution
Samsca
Cosmedics
OZEX ophthalmic solution 4
5
Intraocular irrigating solution
Co-marketing with
Senju Pharmaceutical
Co., Ltd.
OPEGUARD NEO KIT 5
UL• OS
InnerSignal
Topical new quinolone antibacterial agent
Acuatim
6
OTC Drugs
Anti-mycotic agent
Licensed by
Denka Seiken Co.,
Ltd.
Palavale
Pletaal
Oronine H OINTMENT
Oronine Solution
NEW SARALIN
Anti-keratosis agent
Urepearl
7
SOYJOY
Licensed by
Eiken Chemical Co.,
Ltd.
SOYSH
SoyCarat
Diagnostics & Medical Equipment
Diagnostic agent for H. pylori infection
UBIT
For Infants
Rapid test for the detection of
anti-H.pylori antibody in urine
[Sold by Bean Stalk Snow]
RAPIRUN H.pylori antibody STICK
Mucosta
Mucosta ophthalmic suspension
Rapid test for the detection of
Streptococcus pneumoniae antigens
RAPIRUN S. pneumoniae
Gerblé
Gerlinéa
Rapid test for the detection of
influenza A and B viral antigens
Quick Navi-Flu 6
Rapid test for the detection of
adeno viral antigens
UBIT
Quick Navi-Adeno 6
Rapid test for the detection of
respiratory syncytial virus antigens
Quick Navi-RSV 6
Rapid test for the detection of
norovirus antigens
Omugi Seikatsu
Quick Navi-Noro 2 6
Series of urinalysis test strips for
compounds / metabolites
Buslfex
Uropaper III ‘Eiken’ 7
Test kit for the measurement of WT1 mRNA
WT1 mRNA Assay Kit II
‘OTSUKA’
RIA kit for sialyl Lex-i antigen in serum
SLX ‘OTSUKA’
Infrared spectrophotometer for the
measurement of 13 CO2 level in the breath
SPRYCEL
POCone
Fingertip blood sampler
Fingraph
8 9
UL• OS
InnerSignal
BeanStalk POCARI SWEAT
BeanStalk Organic Apple
BeanStalk Organic Barley tea
BeanStalk Feeding bottle & teat
BeanStalk Skin Care Series
Research
and
Development
Pharmaceutical Business
Research policies:
– Put patients first and follow the untraveled path
– Embrace the challenge of developing pharmaceuticals in a highly original way
– Develop pharmaceuticals in fields where treatments are unsatisfactory and patient medical
needs remain unfulfilled
– Take a tenacious approach to intractable diseases
– Insightfully evaluate the outcomes of treatments
and clinical trials
– Pursue first-in-class and world-first drugs
Areas of Focus
Nutraceutical Business
Development of nutraceutical business products begins with a scientific evaluation of the potential health
benefits of the product. New attributes such as taste,
appearance and portability are then conceived to appeal to people’s interest in maintaining and improving
their health.
Research Institutes
Central Nervous System, Oncology, Gastrointestinal (GI),
Cardiovascular, Respiratory, Infectious Diseases,
Ophthalmology, Dermatology
In the field of central nervous system disorders,
Otsuka is conducting global co-development of the
next-generation antipsychotic brexpiprazole
(OPC-34712) with H. Lundbeck A/S, a Danish company with which we have entered a global alliance.
The two companies believe that brexpiprazole
could go well beyond the antipsychotic ABILIFY
and treat a wider range of disorders. In March 2013,
Otsuka also signed a co-development and
co-marketing agreement with Lundbeck for its new
compound Lu AE58054, which is currently under
development as an adjunct treatment for Alzheimer’s
disease. This is one of up to five new compounds
that the company has the opportunity to work on
with Lundbeck under the global alliance.
In June 2012, Otsuka Pharmaceutical also entered
into a global license agreement with Proteus Digital
Health, Inc., to utilize Proteus digital technology in
Otsuka central nervous system drugs. The alliance
aims to develop and market a new category of pharmaceuticals, the world’s first ‘digital medicines.’
This technology will enable physicians to propose
more insightful treatment methods by providing
precise patient information, including when a medication has been taken as well as sleep patterns.
In ophthalmology, Otsuka Pharmaceutical has
formed an alliance with Acucela Inc. The two companies are carrying out co-development of a dry eye
treatment, as well as treatments for glaucoma and
dry age-related macular degeneration (dry AMD),
which are leading causes of blindness.
In 2012, research results on two of Otsuka Pharmaceutical’s drugs were published in the New England
Journal of Medicine, one of the world’s leading
medical journals.
In July 2013, Otsuka Pharmaceutical established
Otsuka Europe Development and Commercialization,
Ltd. (OEDC) in London, U.K. OEDC will be Otsuka
Pharmaceutical’s European clinical development
headquarters, collaborating with Otsuka Pharmaceutical Europe Ltd. (OPEL) on the development and
commercialization of drugs discovered by Otsuka.
Tokushima
Tokushima Research Institute
First Institute of New Drug
Discovery
Third Institute of New Drug
Discovery
Microbiological Research
Institute
Medical Chemistry Research
Institute
Qs’ Research Institute
Formulation Research Institute
Basic Technical Research
Institute
Diagnostic Division, R&D
Department
Shiga
Fujii Memorial Research Institute
Hyogo
Ako Research Institute
U.S.
Otsuka Maryland Medicinal
Laboratories, Inc.
China
Otsuka Shanghai Research
Institute
Clinical Development
Japan
Headquarters of New Product
Evaluation and Development
Diagnostic Division, R&D
Department
U.S.
Otsuka Pharmaceutical
Development &
Commercialization Inc.
U.K.
Otsuka Europe Developement &
Commercialisation, Ltd.
China
Otsuka Beijing Research Institute
Germany
Otsuka Frankfurt Research
Institute GmbH
South Korea
Korea Otsuka Pharmaceutical
Co., Ltd.
Creating Globally Appealing Products
Otsuka Pharmaceutical’s unique, precisionmanufacturing-inspired approach revolves around
two essential R&D principles: the pursuit of bold
paths rather than worn ones to create value available nowhere else, and the development of globally
appealing products.
Otsuka Pharmaceutical launched POCARI SWEAT
in 1980 based on the concept of a rehydration
beverage. Today, it has grown into an international
product sold in 17 countries and regions. And
now, with the help of one of the researchers who
developed POCARI SWEAT – who is currently
serving as an advisor – the company has developed
POCARI SWEAT ION WATER, after six years of
effort, as a beverage suited to the current social
environment. The product was launched in April
2013 as a new style of POCARI SWEAT that offers a
light sweetness and a refreshing taste with reduced
calories while maintaining the functionality of
the original POCARI SWEAT. Thirty-three years after
the launch of POCARI SWEAT, Otsuka will now
promote POCARI SWEAT ION WATER as a product
that offers new value for today’s lifestyles.
The company is also committed to an intense R&D
effort on soy-based products under the concept of
Soylution – that soy can provide solutions to human
health and environmental issues. The company’s
two research institutes in Tokushima are dedicated
to soy food product development. Their results led
to the launch of the sparkling soy water SOYSH
in 2010 and of the healthy soy snack SoyCarat in
2012. Going forward, Otsuka will continue to search
for tastes and food forms that put the nutrition of
soy within easy reach of people around the world.
Nutraceutical Business
Products Research
Tokushima
First Research Institute of
New Functional Products
Development
Second Research Institute of
New Functional Products
Development
Shiga
Otsu Nutraceuticals Research
Institute
Biwako Institute / Otsuka Foods
Co., Ltd.
Saga
Saga Nutraceuticals Research
Institute
Thailand
Otsuka Saha Asia Research
Co., Ltd.
Adding Value Based on
Scientific Evidence
Otsuka’s research into nutraceutical products does
more than develop products in new categories.
Even after a product is launched, the company’s
in-house research facilities such as the Saga Nutraceuticals Research Institute and the Otsu Skin
Care Research Institute cooperate with third-party
research institutes to produce various research
results designed to generate new forms of added
value related to water and nutrition replenishment
and skin health. The goal is always to help people
maintain and improve their health.
Skin Care Research Institute
Shiga
Otsu Skin Care Research
Institute (Cosmedics)
more information
www.otsuka.co.jp/en/research/
10 11
Production
Quality, Safety, Production Cost, and
the Environment
Otsuka Pharmaceutical’s production division
works tirelessly to ensure a stable, highquality supply of originally designed products.
Manufacturing site safety and protection of
the environment are paramount considerations
wherever we operate. Technological cooperation
and personnel exchanges are implemented
across group companies globally, ensuring a
stable supply of products for each market.
Technology Development
Leverages Otsuka’s
Two Core Businesses
Otsuka Pharmaceutical’s unique products
often require new manufacturing methods,
which requires behind-the-scenes creativity
from the company’s production teams.
The people involved in production technology, plants, and quality control work
closely together to set up new lines, develop
production and supply systems and make
continual improvements. Their willingness
to take on new challenges is a foundation
for Otsuka’s innovative products and
growth worldwide.
In 2013, Otsuka Pharmaceutical launched
in the U.S. the antipsychotic drug
Abilify Maintena, a once-monthly, extended
release injection. The production process for
Abilify Maintena makes use of Otsuka
Pharmaceutical’s original aseptic filling
technology, which was developed thanks to
its dual business model of pharmaceuticals
and nutraceuticals. Going forward, Otsuka
Pharmaceutical will keep leveraging
the results of its own unique brand of
technological innovation.
Quality
Safety
Production
Cost
the
Environment
World-class Environmental
World-class
Environmental
Initiatives: Global
Deployment
Initiatives:
Global
of Eco-friendly PETDeployment
Bottles
of Eco-friendly PET Bottles
Otsuka cherishes a spirit of craftsmanship
Otsukaremaining
cherishesmindful
a spirit of
while
of craftsmanship
the environment
while
remaining
mindfuland
of the
environment
in its product
designing
manufacturing
in its product
designing
and
manufacturing
processes.
The
company’s
new
eco-friendly
processes.
company’s
eco-friendly
PET
bottlesThe
weigh
30% less,new
through
use of
PET
bottles weigh 30%
less, through
use of
the positive-pressure
aseptic
filling method.
thepresent,
positive-pressure
asepticbottle
fillingismethod.
At
the eco-friendly
used for
At
present,
the eco-friendly
bottle
used for
POCARI
SWEAT,
Amino-Value,
andisenergen.
POCARI SWEAT, Amino-Value, and energen.
Otsuka’s POCARI SWEAT factory in Indonesia has also adopted this filling method,
which reduces energy use and greenhouse
gas emissions from manufacturing. The
switch to eco-friendly bottles also helps save
resources, reducing not only raw materials to make containers but also energy for
transportation and water required to wash
containers. Ingenuity and attention to detail
in areas such as labels and weight of outer
cases also help Otsuka deliver on its responsibilities to the global environment.
Pursuing the Ideal in
Environmentally Friendly
Production
Tokushima Itano Factory
The Tokushima Itano Factory displays
ecosystem integrity, for instance by
ensuring that facilities are in harmony with
the original setting and that native trees
are protected. At an on-site biotope pond,
employees work to protect and propagate
endangered species. It also co-sponsors the
Asan Earth Festival, a health event organized by the local authorities every autumn.
Factory grounds are open for walking events
and other initiatives to protect human
health and the natural environment.
Location of Major Affiliates Which Own Manufacturing Sites
Tokushima
Tokushima Factory
Second Tokushima Factory
Tokushima Wajiki Factory
Tokushima Itano Factory
12 13
Manufacturing Presence of
Otsuka Pharmaceutical Affiliates
Production (Japan)
Gunma
Takasaki Factory
Shizuoka
Fukuroi Factory
Saga
Saga Factory
139 Factories
14 Countries and regions
38 companies
as of March, 2013
more infomation
www.otsuka.co.jp/en/company/production/
Pharmaceutical Business
People Make the Company Run;
People Do the Thinking
a method was developed for modifying the structure of
‘‘ When
compounds, and thereby developing pharmaceutical products, using
The Untraveled Path
to Drug Discovery
a computer, I thought about closing down the company completely.
If a computer can do the work without human contribution, then it
seemed likely that small companies unable to purchase supercomputers
would be put out of business. But the nature of research belongs to
people. The large multinational corporations that are capable of
buying supercomputers are struggling to develop new drugs; they are
actually buying compounds and developed products from smaller
venture companies. Someone told me that ‘Otsuka Pharmaceutical is a
large venture company.’ People make the company run; people do the
thinking. Otherwise, we’d be in trouble.
Otsuka Pharmaceutical’s drug discovery research began in 1971. The
company established its first in-house drug research institute in its
hometown of Tokushima based on Akihiko Otsuka’s strong determination to follow the untraveled path as a manufacturer that would develop its own drugs. There were 14 young researchers full of dreams
at that original research institute. The essence of research at Otsuka
is high-touch human ingenuity. Here, researchers do not depend on
computers for insights; on the contrary, they use their own minds to
form hypotheses and then test them with their own hands. This approach is what keeps Otsuka Pharmaceutical always on untraveled
paths toward new inventions.
‘‘
Comment by Akihiko Otsuka
in Hitto no Keiei-Gaku, Nikkei Publishing Inc.
Pursuing the Unlimited Potential
of a Single Compound
Only ten years into drug discovery, Otsuka launched Japan’s first beta blocker
Mikelan and the bronchodilator Meptin, which later became the national standard
for asthma treatment. Launch of the antiplatelet agent Pletaal, the anti-gastritis and
the anti-gastric ulcer agent Mucosta, and other drugs followed. All these drugs are
carbostyril-based. The success of drug development based on the unlimited potential
of carbostyril is the very basis of Otsuka’s drug research today.
Drug discovery at Otsuka Pharmaceutical is picking up speed. In 2009, the company
launched Samsca (tolvaptan), a drug that promotes aquaresis (excretion of water
without electrolyte loss), in Japan, the U.S., Europe and elsewhere in Asia. Then, in
2012, Otsuka launched Mucosta Ophthalmic Suspension for the treatment of dry eye,
an innovative medicine discovered by adapting the mucin production-stimulatory effect of rebamipide, the main ingredient in the anti-gastritis and the anti-gastric ulcer
agent Mucosta.
2013
2013
Akihiko Otsuka and three Otsuka Fellows (research specialists)
CI
CI
• H2 O
Abilify Maintena
N
2012
O
N
H
N(CH 2 ) 4 O
Three Drugs with World-first
Mechanisms of Action
CNS
Once-Monthly Injection of Abilify Maintena Launched in U.S. –
Aiming to Reduce Schizophrenia Relapse
Otsuka Pharmaceutical is committed to the development of pharmaceuticals
with world-first mechanisms of action. World-first compounds hold the seeds
of new drugs in completely new categories. Under the leadership of Akihiko
Otsuka, the company’s researchers gained experience using a non-drowsy
antihistamine to develop dopamine D2 receptor agents in the central nervous
system. Taking a hint from this, they developed ABILIFY, which has a worldfirst mechanism of action, and launched it in the U.S. in 2002. Today, ABILIFY
is sold in 60 countries and regions for 13 indications. Going a step further,
Otsuka Pharmaceutical developed Abilify Maintena, an injection with one
month of sustained efficacy, as a new method for improving patient compliance. The product was launched in the U.S. in 2013.
Mucosta
ophthalmic suspension
CH 3
CO
N
2009
CONH
Samsca
OH
CH 3
CI
2002
2002
CI
Vasopressin
CI
N
ABILIFY
N
H
N(CH 2 ) 4 O
O
NHCO
CI
CH 2 CHCOOH
1990
Mucosta
N
N
N
H
O
N
N
H
O
1980
CH 2 CH 2 CH 2 CH 2 O
Pletaal
1980
OH C 2 H 5
CH – CHNHCH(CH 3 ) 2
• HCl • 1/2H 2 O
Meptin
N
H
MDR-TB
O
OH
OH
1980
Mikelan
OCH 2 CHCH 2 NHC(CH 3 ) 3
• HCl
1971
1971
14 15
Oral Vasopressin V2 - Receptor Antagonist Samsca –
The Unlimited Potential of a World-first Mechanism of Action
Otsuka Pharmaceutical’s research into vasopressin started in 1983, when
Akihiko Otsuka, then-president of Otsuka Pharmaceutical, spoke with a physician to find out what doctors really wanted in order to supplement their daily
medical practices. Diuretics were conventionally used to treat patients with
edema, although this caused excretion of essential electrolytes as well, rather
than just the water that causes the swelling. A drug which could do this did
not exist.
Otsuka Pharmaceutical spent 26 years working on this difficult challenge.
The result was the successful development of tolvaptan, a diuretic with a
world-first mechanism that promotes the excretion of only water, without
forcing electrolytes out of the body. The product was first launched in 2009 in
the U.S. as the oral vasopressin V2 -receptor antagonist Samsca and
is now available in 14 countries and regions.
Making use of another mechanism of tolvaptan other than aquaresis,
Otsuka Pharmaceutical is attempting to develop a treatment for autosomal
dominant polycystic kidney disease (ADPKD), a genetic kidney disease for
which there is currently no treatment.
N
1988
Central Nervous System
N
H
O
N
H
O
OH
Carbostyril-based
Drugs
A Treatment for Multidrug-Resistant Tuberculosis (MDR-TB) –
Never Giving Up
About a third of the world’s population, or 2 billion people, is infected with TB
bacteria, and each year about 8.7 million people develop multidrug-resistant
tuberculosis (MDR-TB), which is particularly difficult to beat. It is estimated
that each year about 440,000 people develop MDR-TB, and 150,000 lose their
lives. Otsuka Pharmaceutical’s development of antimicrobial agents started
through the inspiration of Otsuka’s chairman Akihiko Otsuka, who established
a drug research institute in 1971. Few people understood the significance
of this development, including at the time when research into a TB drug got
underway, and the research involved a high degree of risk. Pursuing research
in a field that most ignored at times seemed like a long, solitary and unending
road. However, after more than 30 years of R&D, Otsuka Pharmaceutical filed
for regulatory approval of Delamanid in Europe and Japan for the treatment
of MDR-TB.
Pharmaceutical Business
The Unlimited Potential of a World-first Mechanism of Action
Samsca:
The Oral Vasopressin
V2 -Receptor Antagonist
‘‘ I believe at least first-
in-class drugs are
in a sense ‘hand-made.’
The most important thing
is trusting in people’s
skills and intelligence.
‘‘
The Challenge of Developing
a First-in-Class1 Drug:
A Diuretic That Promotes Excretion of Only Water
Yoichi Yabuuchi
Executive Fellow, Research
Vasopressin
‘What kind of drug do you want?’
‘A diuretic that only excretes water.’
One day in 1983, Akihiko Otsuka, the former
president of Otsuka Pharmaceutical, spoke with a
physician to find out what doctors really wanted
in order to supplement their daily medical practices.
Diuretics were conventionally used to treat patients
with edema, although this caused excretion of
essential electrolytes as well, rather than just the
water that causes the swelling. A drug which
could do this did not exist.
Otsuka Pharmaceutical spent 26 years working on
this difficult challenge. The result was the successful
development of tolvaptan, a diuretic with a worldfirst mechanism that promotes the excretion
of only water, without forcing electrolytes out of the
body. The product was first launched in 2009 in
the U.S. as the oral vasopressin V2 -receptor
antagonist Samsca and is now available in 14
countries and regions.
Samsca Global Brand Team
A Hand-made, World-first Drug
from Japan
The Unwavering Quest for Discovery:
R&D Driven by a Shared Goal and
a Freewheeling Exchange of Ideas
It was Yoichi Yabuuchi, who
today presides over research
as a fellow, who led Otsuka
Pharmaceutical’s researchers
in the development of this
groundbreaking compound,
which promotes the excretion of only water, without
forcing electrolytes – such as
sodium – out of the body. The
specific development goal
was to inhibit vasopressin,2
the anti-diuretic hormone
controlling the reabsorption
of water from urine back into
the blood to maintain body
fluid balance.
It also had to be available
orally, to make it convenient
for patients. Research commenced in 1984, and it took
three years before a prototype compound was identified following screening and
synthesis of several thousand
compounds.
16 17
Then-president Akihiko
Otsuka suggested casual
meetings over a meal in
order to encourage the
researchers never to give
up on their quest and keep
their spirits up despite the
repeated failures. Bermuda
shorts were then in vogue
and at a series of ‘Bermuda
Meetings,’ everyone from the
president to lab assistants
wore the same casual shorts
and enjoyed the camaraderie
of working toward a shared
goal that would eventually
become Samsca. Stereotypes
and hierarchy were set aside
to energize and accelerate
creativity.
In 1989, researchers had
successfully synthesized
Physuline (mozavaptan),
which was the world’s first
oral non-peptide V2 - receptor
antagonist. It later led to
the development of Samsca
(tolvaptan).
Yoichi Yabuuchi likes to say,
‘First-in-class drugs are in
a sense hand-made ’. Drug
discovery at Otsuka is artisanal, and it takes time,
faith, and immense effort for
researchers to create a drug
like Samsca, which took
26 years. Samsca was
launched initially in 2009
in the U.S., the U.K., Germany and other European
countries, followed in 2010
by Japan and in 2011 other
Asian countries and extending to a total of 14 countries
and regions today.
Samsca’s approved indications differ depending on
the country or region. The
indication in the U.S. and
Asian countries is hyponatremia, and in Europe it
is hyponatremia caused by
the syndrome of inappropriate secretion of antidiuretic
hormone (SIADH). In Japan,
Samsca has been marketed
since December 2010 as the
first free water clearance drug
(aquaretic) with the world’s
first indication for fluid
retention in heart failure. An
additional efficacy application
was approved in September
2013 for fluid retention
in liver cirrhosis. Samsca
7.5 mg tablets were launched
in Japan in June, adding
to the existing 15 mg tablets.
Going forward, Otsuka
Pharmaceutical will continue
development on new potential uses to enable Samsca to
benefit patients through optimal treatment, in response
to the different needs of each
country and region. The company will keep pursuing the
limitless potential of this drug
attained through pursuing
R&D on untraveled paths.
The medical profession
tentatively explored uses
for Samsca when it was
first launched, trying to get
acquainted with this new,
first-in-class drug. As professionals in different countries
discussed their experiences, a
body of treatment knowledge
emerged. Today, Samsca’s
uniqueness is appreciated
in medical settings and the
value of promoting excretion
of water without electrolyte
loss is gaining recognition
around the world.
1 First-in-class:
Effi cacious new pharmaceuticals with
unprecedented mechanisms of action.
2 Vasopressin:
A hormone that suppresses diuresis.
It binds to the V2 - receptors in the
collecting duct system of the kidneys
and reduces the amount of urine by
re-absorbing water from the urine
and returning it to the bloodstream.
The active ingredient in Samsca,
tolvaptan, reduces the amount of
water re-absorbed in the collecting
duct system of the kidneys by
blocking vasopressin V2 -receptors.
The result is that water alone – not
sodium or any other electrolytes –
is eliminated from the body.
Otsuka Pharmaceutical
continues to promote Samsca
with the vision of giving the
globe a world-first drug made
in Tokushima, Japan.
Resolutely Unique Research Wins the Pharmaceutical Society of
Japan Award for Drug Research and Development 2013
The discovery of the vasopressin
V2 -receptor antagonist
tolvaptan was chosen for the
Pharmaceutical Society of Japan
Award for Drug Research and
Development 2013, in recognition
of the 26 years of effort and
enthusiasm that culminated in
the creation of this first-in-class
drug.
Pharmaceutical Business
Multidrug-resistant
Tuberculosis
Taking Up the Fight
Against MultidrugResistant Tuberculosis
MDR-TB
It has been 45 years since the introduction of the last new
mainstay anti-TB drug rifampicin. However, multidrug-resistant
tuberculosis (MDR-TB), which is resistant to these older mainstay
treatments, has become a problem in recent years, further
highlighting the worldwide need for new treatments.
Otsuka Pharmaceutical has been working on the development of
antibiotics and antimicrobial agents since the opening of its
original drug research institute in 1971. Aiming especially at the
development of an anti-TB drug, today Otsuka is the world’s
top private sector investor in the field of anti-TB drug development.1
‘‘ Mycobacterium tuberculosis is an
A Third of the
World’s Population
Is Infected with TB
1
TAG（Treatment Action Group）2012,
Report on Tuberculosis
2
WHO-Global Tuberculosis Report
2012
3
WHO-Multidrug and extensively
drug-resistant TB(M/XDR-TB)-2010
Global Report On Surveillance
And Response
4
China, Egypt, Estonia, Japan,
South Korea, Latvia, Peru,
The Philippines, U.S.A.
18 19
TB is sometimes referred to
as the ‘forgotten disease.’
In the modern age when so
many medical advances have
been made, few people are
concerned that TB is still a
serious infectious disease for
the world.
‘‘
Dyed magnifi cation of
tuberculosis bacteria
(Rights from Otsuka S.A.)
Even in today’s world, where
medical science is continually
advancing, TB is still rampant.
Nearly a third of the world’s
population is infected with
TB bacteria, and each year
about 1.4 million people die
as a result of developing
active TB.2 In addition, there
are an estimated 440,000
patients with MDR-TB, and
some 150,000 of those are
said to lose their lives to the
disease each year.3
extremely tenacious pathogen. Driven
by a desire to help the large number
of patients suffering from TB, Otsuka
Pharmaceutical has kept searching
for a unique and unconventional
approach in order to discover a new
drug that fights the disease.
New Drug Application
Targeting MDR-TB
Submitted in Japan
in March 2013 after
World’s Largest-Ever
Clinical Trial for TB
Conducted in Nine
Countries
In June 2012, results of a
phase II clinical trial that assessed the efficacy and safety
of delamanid in patients
with MDR-TB were published
in the globally authoritative
New England Journal of
Medicine. The trial enrolled
481 study subjects at
17 medical institutions in
9 countries.4 Based on the
results of clinical trials
such as this, Otsuka
Pharmaceutical submitted
new drug applications for
delamanid seeking an indication of treatment of MDR-TB
in Europe in 2011 and in
Japan in 2013. Otsuka
Pharmaceutical is one step
closer to a dream it has
pursued for more than
30 years.
Hiroshi Ishikawa
Fellow, Medicinal Chemistry
Tuberculosis
Global Project Team
Fighting Back – Efforts to Beat TB
Under the slogan of ‘Fight Back,’ Otsuka Pharmaceutical’s global tuberculosis
business exemplifies creative originality while thinking of patients and fighting to
give them a cure. Serious about this dream, Otsuka Pharmaceutical centralized its
functions related to TB care and management in Otsuka S.A. in Geneva, which
is home to many international health organizations.
Recently, Otsuka implemented an advance project in the Republic of Moldova in
Europe, which has one of the largest MDR-TB epidemics in the world. The program
supports TB diagnosis, offers guidance to minimize TB infection within hospitals,
and provides support so that patients can complete treatment while maintaining
interaction with their families and communities. The company is also working to
build awareness about TB. A photo book, produced with the cooperation of the
European Respiratory Society, features the status of TB patients around the world.
Otsuka is committed to the fight against TB, and it has the global team of
knowledgeable and passionate professionals needed to win it.
Pharmaceutical Business
A Once-Monthly Injection That Delays Schizophrenia Relapse
The Antipsychotic
Abilify Maintena
Launched in the U.S.
Aripiprazole, a compound discovered by Otsuka,
has led to the creation of another innovative
product: the once-monthly, extended-release
injection Abilify Maintena. In March 2013, the
product was launched in the U.S. through codevelopment with the company’s alliance partner
H.Lundbeck A/S. This new drug, which was developed based on the antipsychotic ABILIFY, maintains
its therapeutic effect for one month with a single,
long-acting injection. Evidence that this can lower
the hospitalization rate caused by relapse of
psychotic symptoms in patients with schizophrenia
was presented at the American Psychological
Association (APA) Annual Meeting in May 2013.
Abilify Maintena offers a new option to patients
who have difficulty taking their medication
every day.
Otsuka has also made progress in Japan in the
central nervous system (CNS) field in new
product categories. In February 2013, it launched
Neupro Patch, a drug indicated for both Parkinson’s
disease and restless legs syndrome, in-licensed
from UCB of Belgium. In May 2013, it obtained
approval for pediatric epilepsy as an additional
indication for the antiepileptic drug E Keppra. The
company is pressing ahead to find better
treatments for various CNS disorders, including
Alzheimer’s disease.
CNS
Central Nervous System
Media Exchange in Tokushima on March 7, 2013
60
Helping Patients by
Expanding Treatment into New Categories
of Psychiatric Illness
Aripiprazole, a compound
discovered by Otsuka
Pharmaceutical, has undergone R&D for 25 years at
a research institute in the
company’s hometown of
Tokushima. First delivered to
patients as the antipsychotic
ABILIFY in the U.S. in 2002,
today the drug is prescribed
in 60 countries and regions
worldwide.
The product has contributed
to the social reintegration
of numerous patients with
schizophrenia. With a novel
mechanism of action as a
dopamine D2 receptor
partial agonist, it has an
excellent efficacy and safety
profile.
For patients with psychiatric
illnesses such as schizophrenia, ABILIFY’s advantageous
profile on adverse reactions
is an important factor affecting how long patients can
keep taking their medication.
The product’s high level of
safety has facilitated additional indications in new categories not typically treated with
an antipsychotic. At present,
13 indications have been approved worldwide.
Prescriptions for the additional medical indications of
depression and pediatric disorders now account for about
50 % of ABILIFY prescriptions
in the U.S.
Depression
Number of countries
and regions where ABILIFY
is marketed
Backed by the appreciation
and confidence of patients
and healthcare professionals,
ABILIFY, which was created
without emulating other
antipsychotics or following
existing trends in CNS research, attained blockbuster1
status only three years after
its launch in the U.S. It subsequently grew to achieve the
No. 1 sales position among
all drugs in the U.S. from
October through December,
2012, and again from January
through March, 2013.2
ABILIFY was the No.1 seller
among all drugs in the U.S. in
the fourth quarter of 2012
and the first quarter of 2013.
13
Number of indications
worldwide for ABILIFY
(as of June 2013)
1 Blockbuster:
A new drug that revolutionizes existing treatments and generates enormous sales and profi ts. The defining
milestone is peak annual sales of over
USD 1 billion.
2
© 2013 IMS Health MIDAS
Quantum 1Q/2013
Estimated based on ‘Sales date’
Reprinted with permission
Next Step
Pediatric
Bipolar disorder
Schizophrenia
‘Creativity’ and ‘Proof through Execution’
Based on its corporate philosophy, Otsuka Pharmaceutical aims to contribute to the better health of people
worldwide by creating innovative products and then
executing on the hard work it takes to demonstrate
their value. During the exchange with the media held in
Tokushima on March 7, 2013, Taro Iwamoto, President,
Otsuka Pharmaceutical Co., Ltd. (at left in photo)
and Ulf Wiinberg, CEO, H. Lundbeck A/S, described the
latest accomplishments of ‘creativity’ and ‘proof through
execution’ against the backdrop of calligraphy
featuring the first characters in the Japanese terms for
these two concepts.
20 21
No.1
Pharmaceutical Business
Two Innovative Approaches to
Tackling the Challenges of
Central Nervous System Disease
about
60 %
1. Development of Drugs in New Categories
The central nervous system
is one of the most challenging research areas for drug
discovery and development,
even for companies with
extensive experience in this
area. In order to create new
value through innovation,
Otsuka believes that it must
complement its independent efforts with horizontal
collaborations with alliance
partners. Otsuka and alliance
partners think through challenges in an atmosphere of
equality, idea sharing and
friendly competition, and this
leads to new breakthroughs.
Seeking to help even more
patients, Otsuka Pharmaceutical entered into an alliance
with U.S.-based BristolMyers Squibb (BMS), which
started marketing ABILIFY in
the U.S. in 2002.
In joint research with
Lundbeck, Otsuka is undertaking a phase III clinical trial
on the next-generation
antipsychotic brexpiprazole
(OPC-34712), which is hypothesized to have a safety
profile even better than
ABILIFY and is expected to
provide benefits for a wide
range of CNS diseases. The
two companies have also
agreed to pursue phase III codevelopment of a compound
developed by Lundbeck as
a treatment for Alzheimer’s
disease.
Additionally, the antiepileptic
drug E Keppra, which Otsuka
Pharmaceutical is working
on together with the Belgian
company UCB, received approval in Japan in May 2013
for a pediatric indication.
Backed by a pediatric record
in over 80 countries and regions around the world,
E Keppra offers a new, lessworrisome treatment option.
In 2012, Otsuka also began
marketing in Japan for
Neupro Patch, which maintains a constant effect for
24 hours, for patients with
diseases such as Parkinson’s
disease. By listening to the
voices of Parkinson’s patients
before launching Neupro
Patch, Otsuka identified
where the unmet treatment
needs were. Otsuka offers
Neupro Patch as a drug in a
new category aimed at alleviation of Parkinson’s disease
symptoms that occur at night
and in the early morning.
2. Helping Patients Who Cannot Keep Taking Their Medication
Uninterrupted adherence to
medication is a main predictor of symptom relapse in
patients. That is why pharmaceutical companies have
developed many formulations
that are easy for patients to
take, such as pills and liquids.
The fact is, however, that
patients with schizophrenia
still achieve poor drug adherence compared to patients
with other diseases. This is a
serious challenge, as it is
related to an increased rate
of symptom relapse.
Approximately 80% of
patients with schizophrenia
who do not adhere to their
drug regimen are said to
suffer a relapse of symptoms
within five years. To counter
this, Otsuka took aripiprazole,
a compound it had developed,
and used it to develop an
injection that would maintain
the drug’s effect with a oncemonthly administration instead of daily dosing, seeking
to introduce a new method
for increasing treatment
compliance. In 2011, after
forming a co-development
and co-marketing alliance
with Lundbeck, the companies
stepped up research into a
depot injection, which obtained regulatory approval
as Abilify Maintena in the
U.S. in 2013. Now Otsuka has
established a new marketing
system in horizontal collaboration with Lundbeck.
Development of the Antipsychotic ABILIFY (Aripiprazole) –
Pursuing the Unlimited Potential of a True Original
to imitate leads to creativity.
And researchers are
encouraged to continue
until they obtain results.
This element of the Otsuka
Group’s corporate culture
led to the discovery of
the compound aripiprazole.
Inheriting the results of their
predecessors, the research
team of Yasuo Oshiro, who
was responsible for synthesis, and Tetsuro Kikuchi,
who was responsible for
pharmaceutics, spent 25
years engaged in research
without giving up hope. Their
committed efforts led to the
creation of aripiprazole as
the world’s first antipsychotic
that acts as a dopamine D 2
receptor partial agonist and
its successful commercialization as ABILIFY.
‘‘
Through its experience developing a drug that stimulates
dopamine autoreceptors in
the presynaptic region of the
brain, Otsuka Pharmaceutical
went against worldwide conventional wisdom in research
and continued pursuing the
potential of a new compound
with a revolutionary mechanism of action.
Aiming to further increase
treatment adherence,
Otsuka Pharmaceutical is
also working to introduce a
groundbreaking combination
of a central nervous system
drug with an ingestible
sensor system that applies
technology developed by
U.S.-based Proteus Digital
Health, Inc., to monitor
patients’ drug-taking patterns.
Knowing precisely when
patients take their medication and when they sleep will
enable medical professionals
to propose the most suitable
treatment methods for
patient recovery.
‘‘ A uniqueness that refuses
Searching for
an Original Mechanism of Action
Drug development for CNS
diseases is challenging, and
the success rate is said to
be extremely low. While
groundbreaking new drugs
appeared one after another
for other diseases, patients
with schizophrenia suffered
from the adverse drug
reactions of their only option:
drugs which completely
block dopamine receptors in
the brain, often referred to
as first-generation drugs.
Development of secondgeneration drugs followed.
Percentage of patients found not to be taking their
antipsychotic medication: 61.9%
Compliance verifi cation using a device that counts
the number of times a microchip-embedded bottle
cap has been removed (data from outside Japan)
Byerly, M.: The 41st Annual Meeting of the
American College of Neuropsychopharmacology,
Dec. 10, 2002
Tetsuro Kikuchi
Fellow-Qs’ Research Institute,
Director
Three Aripiprazole Synthesis Researchers Win Fiscal 2013
Imperial Invention Prize at the National Commendation for Invention
Yasuo Oshiro, Ph.D.,
Corporate Advisor, Intellectual
Property Department (center)
22 23
In June 2013, an award ceremony was held in Tokyo for the National
Commendation for Invention, which has been presented since 1919 for
outstanding reseach-driven inventions that contribute to the progress of
science and technology and the development of industry in Japan.
In 2013, the invention of aripiprazole was selected for the Imperial
Invention Prize, which is presented for the most outstanding invention.
This prize recognizes the resolutely original R&D of Yasuo Oshiro and
his colleagues, who discovered and succeeded in synthesizing a compound
characterized by few adverse drug reactions that can be used safely.
“Receiving the Imperial Invention
Prize is the highest honor. I never
imagined being awarded this
prize. As someone working in
drug research and development, it
is extremely gratifying to receive
this award. I am fortunate to be
surrounded by colleagues who
have offered me their unwavering
support and encouragement. None
of what I have achieved would
have been possible without the
help of such exceptional coworkers
in the fields of drug synthesis and
pharmaceutics.”
Seiji Sato, Ph.D.,
Senior Researcher, First Institute
of New Drug Discovery,
Medicinal Chemistry Group (left)
“Failure is common in our field,
drug synthesis. The hard work is
tackled first. You are constantly
aware of the obstacles that you
have not been able to overcome in
the past, and you keep trying over
and over again to overcome those
challenges because beyond them
lies success and you will discover
new findings along the way.
Partial agonists are at first glance
a difficult concept to believe in.
I think Dr. Oshiro’s courage in
taking that first step to tackle this
concept, as well as the strength of
his conviction, were the driving
forces behind this achievement.”
Nobuyuki Kurahashi,
Vice President, Global CNS
Business, Otsuka America
Pharmaceutical, Inc. (right)
“Dr. Oshiro incorporated ‘safety’
in the drug design from the very
beginning. When aripiprazole
was introduced to the market,
these excellent ‘safety’ properties
earned widespread praise from
doctors, families, and patients.
Also because of this feature,
aripiprazole has been used for
so many patients and so many
diseases beyond the conventional
drug category. Ever since I joined
the company, it has brought
me great honor to be involved
with this drug, from its initial
discovery through to its market
launch worldwide.”
Nutraceutical Business
Nutrition
+ Pharmaceuticals
2013
POCARI SWEAT
ION WATER
= NUTRACEUTICALS
The History of Nutraceuticals
The seeds of today’s successful pharmaceutical
business were planted in 1971, when Otsuka
Pharmaceutical launched its first independent drug
discovery effort. Even then, the company recognized
that pharmaceuticals alone would not be enough
to make the kind of broad contribution to people’s
health it envisioned. Medicines help restore health to
the sick, but the company also wanted to see healthy
people become even healthier. This implied the need
to combine pharmaceutical knowledge with nutrition to help people maintain daily health. This idea
eventually became a reality as the company developed category-defining consumer and nutraceutical
products. This is how nutraceuticals became Otsuka’s
second core business, alongside pharmaceuticals, for
supporting the health of people around the world.
2010
2012
SOYSH
SoyCarat
2006
SOYJOY
1997
Jog Mate
Protain
Today, the Nutraceuticals Division is focused on supporting
people’s day-to-day well-being. The term ‘nutraceuticals,’ a
portmanteau of nutrition and pharmaceuticals, was coined
in 1989 by the American physician Stephen L. DeFelice, who
proposed using this word to describe foods and beverages with
scientific evidence for their benefit in day-to-day health maintenance. Otsuka Pharmaceutical soon saw that the products it
had been creating since the 1970s to help people maintain and
even improve their health fit this definition, and renamed its
consumer products business accordingly.
energen
FIBE-MINI
1983
POCARI
SWEAT
‘‘ We simply oncentrated
ORONAMIN C
DRINK
Otsuka’s businesses
into two categories.
One would help
restore health to the
sick. The other would
help the healthy
stay healthy.
‘‘
Akihiko Otsuka
(then president of
Otsuka Pharmaceutical)
From a New Year’s message
in 1982.
Akihiko Otsuka
24 25
1991
No Consumer Surveys: Let the Flavor
Genius Decide
Calorie Mate
1965
Rokuro Harima
(then staff member of Otsuka Foods
Research Department,
Subsequently chairman of Otsuka Foods)
Rokuro Harima, who invented
ORONAMIN C DRINK and presided
over the developement of POCARI SWEAT
and Calorie Mate, often said,
‘Taste is at the center of everything.’
Chairman Akihiko Otsuka
called him ‘The flavor genius’.
Amino-Value
1993
1988
1980
2003
Starting with the I.V. solution
business it entered in 1946,
the Otsuka Group took on
the challenge of starting
businesses in one field after
another through the 1960s.
First it started a successful beverage business with
the launch of ORONAMIN C
DRINK in 1965. Next, it
created a new market
category with retort-pouch
BON CURRY (a product of
Otsuka Foods Co., Ltd.)
in 1968. Then, in 1980 it
launched POCARI SWEAT.
One man was involved in
the development of many
products that established new
fields (including ORONAMIN
C, BON CURRY, and POCARI
SWEAT): Rokuro Harima.
Harima joined Otsuka
Pharmaceutical Factory as an
engineer in 1951. Later, in
the course of his involvement
with the I.V. solution business,
he made a prototype syrup
using vitamin C, which was
a raw material in I.V. solutions. Otsuka Pharmaceutical
did not conduct consumer
surveys when deciding on
flavors. Instead, as Akihiko
Otsuka later said, the company relied on Harima, ‘the
genius of taste.’ Harima was
able to apply his genius
across Otsuka’s diverse businesses, from I.V. solutions to
beverages, and his syrup
led to the development of
ORONAMIN C, a delicious
carbonated nutritional drink.
theCalcium
Application of
Otsuka’s I.V. Solution
Aseptic Technology
Leads to the
World’s First Curry
Retort Pouch
for Consumer Use
The Otsuka Group’s processed foods business got
its start with the launch of
BON CURRY in 1968. Akihiko
Otsuka and Rokuro Harima,
who were participating in the
management of a company
called CBC Foods Industry
in which the Otsuka Group
had invested at that time,
were aiming to develop a
retort curry that would store
well and could be eaten
just by heating. By applying
know-how gained in various
areas, including sterilization
technology developed for its
I.V. solution business, and
seeking intentionally to create a previously unheard-of
product, the Otsuka Group
succeeded in developing the
world’s first available ‘off-theshelf’ curry in retort pouches.
By applying the knowledge
gained by working with pharmaceuticals, the company’s
efforts all along naturally
led to the creation of today’s
Nutraceuticals Division and
its ongoing development of
trailblazing products.
From Water
to Food:
Pioneering New
Markets That
Contribute to the
Maintenance
of Health
After becoming president in
1976, Akihiko Otsuka shared
with Harima a conceptual
map for the development of
consumer products. On the
left was ‘food,’ on the right
was ‘water,’ and in the middle
was ORONAMIN C, the
product that established
Otsuka’s consumer products
business. The idea was to
develop new products to
cover more of the map, and
it didn’t take long. In 1980
the company launched the
beverage POCARI SWEAT
designed for situations where
people perspire, and in 1983
it released the nutritionally
balanced food, Calorie Mate.
The market did not easily
accept these new products
at first. A light-tasting beverage in an unusual blue can
with a taste unlike any other
drink? A balanced nutritional
food that hardly even looked
like food and came in a
radical yellow package? At
least one thing was clear:
these products were based
on revolutionary concepts.
What gradually dispelled
consumers’ worries about
these forward-looking products was the collective efforts
of Otsuka Pharmaceutical’s
employees. Filled with the determination to give the world
epoch-making products for
supporting day-to-day wellbeing, they tirelessly proposed new ideas that people
had never considered before,
and won the public over day
by day. Their approach blazed
the trail for other groundbreaking products such as the
drinkable fiber FIBE-MINI and
Amino-Value, which supplies
several essential amino acids
for humans. Confident that
its products were based on
completely new concepts and
solid science, Otsuka Pharmaceutical went on to create one
new market after another on
the world stage.
Nutraceutical Business
A New Choice for Modern Lifestyles
POCARI SWEAT ION WATER:
Refreshingly Sweet, Clean Taste,
Low in Calories
Otsuka Pharmaceutical launched POCARI SWEAT
in 1980, based on the concept of quickly replenishing the water and electrolytes (ions) lost while
perspiring during daily activities. The idea was to
make a drinkable I.V. solution. With this inspiration, Otsuka leveraged its strengths as a leading
company in the I.V. solutions business in Japan
to develop the product. Today, POCARI SWEAT is
loved not only in Japan; it is a favorite in 17 countries and regions worldwide.
Meanwhile, changes in people’s tastes and lifestyles led to the need for a less sweet ion beverage that consumers would find easier to drink in
everyday life. Otsuka has always been mindful of
the critical importance of taste in order for more
consumers to enjoy its beverages and foods. As
people’s tastes changed, the company set about to
perfect another POCARI SWEAT with a light
sweetness and refreshing taste suited to modern
life while preserving all the health functions
of the original POCARI SWEAT. The new product,
POCARI SWEAT ION WATER, was launched in
April 2013.
Masayuki Umeno,
Vice President and Representative Director
speaking at the April 2013
launch announcement meeting
2013
Akihisa Takaichi
Corporate Adviser,
Manufacturing Process
Development Department
A Water and Electrolyte
Replenishment Beverage
That Is Best for Today’s Lifestyles
It has been 33 years since
POCARI SWEAT was launched.
People’s tastes and attitude
about caloric intake have
evolved with the changing
times and social environment.
But water and electrolyte
replenishment remain essential for people’s health. Otsuka
Pharmaceutical believes
that the mission of POCARI
SWEAT is to provide what
people need most for today’s
lifestyles.
26 27
“Products do not lie; they
express a company’s ideas
just as they are. Presenting
‘health’ as an appealing
concept to people through
a product and making
the product enticing –
including through flavor
and aroma – are vital
aims. We also must have
the conviction to carry
through until the end.”
The clear-cut concept of
POCARI SWEAT is an ‘ion supply and refreshment beverage.’ The product’s sweetness
had to be toned down while
maintaining its functionality.
Akihisa Takaichi, who was
in charge of developing the
new product, commented
that the work of adjusting the
flavor was even more
painstaking than when the
original POCARI SWEAT was
developed. The development
team repeatedly adjusted
the ingredients one by one in
the slightest of amounts. It
took six years to come up
with a satisfying flavor.
This is how the new product
POCARI SWEAT ION WATER
was perfected.
Inspired by I.V. Solutions:
POCARI SWEAT,
a Beverage for Situations
Where People Perspire
1980
The Birth of
POCARI SWEAT
1973
The Idea for a
Drinkable I.V. Solution
Research underway on
POCARI SWEAT
by Rokuro Harima (right) and
Akihisa Takaichi
About 40 years ago, an
Otsuka researcher named
Rokuro Harima was on a
business trip to Mexico, when
he was hospitalized due to
diarrhea. The doctor told
him to get enough water and
nutrition, and handed him a
carbonated beverage. The
researcher, who already had
the dream of developing an
unprecedented new beverage, thought that it would
be nice to have a drink that
could supply both water and
the nutrients he needed.
Later, in 1973, Harima saw a
doctor drinking an I.V. solution to rehydrate himself after
finishing a surgery. This was
the moment of inspiration
for a drinkable I.V. solution.
With this idea, Otsuka researchers began to develop
a rehydration beverage that
could replenish the water
and electrolytes (ions) lost
while sweating during
daily activities. Pursuing this
idea came naturally for
a leading company in the
I.V. solutions business.
Three years later in 1976,
society had become more
health conscious. Situations
in which people perspire on a
regular basis had increased,
as had the importance of
water and electrolyte replenishment. However, rather
than developing a sports
drink, the researchers, led by
Harima and Takaichi, sought
to create a health beverage
for everyone in situations
where they sweat, so that it
would appeal to more people.
Otsuka researchers continued
R&D on health beverages
that could be enjoyed during
daily activities. Through this
work, the Otsuka researchers
found that there are different kinds of sweat. They also
found that the concentration
of salt in everyday sweat is
lower than in sweat that
occurs during sports activity.
Based on these findings, the
researchers came up with
over 1,000 prototype beverages that recreated the components of everyday perspiration. However, Harima and
his team were having trouble
overcoming the saltiness
and bitterness of the constituents of sweat. One day,
then-president Akihiko Otsuka
suggested they try combining
some of the rejected drinks.
So they mixed a trial rehydration drink with a citrus
powder juice that was also
being developed in the lab at
the same time. Suddenly the
bitter taste was gone, and a
great tasting beverage was
born. Through this combination that no one had ever
considered before, the development of this unprecedented
drink took a big leap forward.
The research continued, and
finally two test products were
prepared: one with high and
one with low sugar content.
At that time sweet, juice-style
beverages were the norm.
However, in order to test the
product concept to develop
a drink that tastes great
especially after sweating and
that goes down so smoothly
you don’t recall that you
even drank it, the researchers did not rely on common
sense. In fact, they actually
climbed a mountain overlooking Tokushima to try out the
test products for themselves.
Then, they realized that the
lightly sweetened test
product was easier to drink
and went down smoothly.
With that, the unprecedented water and electrolyte
replenishment beverage
POCARI SWEAT was launched
in 1980.
Building Awareness about
Heat Stroke for 22 Years
In 1984, Otsuka Pharmaceutical established the Saga
Nutraceuticals Research Institute. Even after the launch of
POCARI SWEAT, the company
carried on with research into
beverages that quickly replenish water and electrolytes
lost through perspiration,
discovering scientific evidence in a range of different
situations. This effort was
propelled by the idea that
POCARI SWEAT could make
the maximum contribution to
people’s health by targeting
situations in which ordinary
people perspire in everyday
life, not just during sports.
Based on this scientific evidence, and stimulated further
by the establishment of the
Study Group for Prevention
of Heat Stroke in Sports
Activities by the Japan Sports
Association in 1991, Otsuka
Pharmaceutical has on its
own and in cooperation with
various organizations worked
strenuously to educate the
public about the importance
of water and electrolyte
replenishment in many different situations, including
measures to counter heat
stroke in school, the workplace, during exercise, and
among the elderly.
Thanks to efforts like these,
understanding of the
original concept behind
POCARI SWEAT spread
slowly but surely, creating
a whole new market
category.
China
Global Expansion
to 17 Countries and
Regions
POCARI SWEAT has moved
onto the world stage. Today
it is available in 17 countries and regions, and sales
outside Japan now exceed
those inside Japan. Sales in
Indonesia, South Korea, and
China have experienced especially marked growth and the
launch in Vietnam in 2012 is
poised to add further growth
in Asia. By adapting to each
diverse culture around the
world while staying true to
the unchanging, sciencebased concept of a beverage
for situations where people
perspire, POCARI SWEAT has
won a special place in people’s hearts for helping them
stay healthy.
17
Hong Kong
South Korea
Middle East
48 million
Thailand
Otsuka Website Page ‘Rehydration’
www.otsuka.co.jp/en/company/
business/rehydration/
28 29
The number of countries and
regions where POCARI SWEAT
is marketed
1980 Japan
1982 Taiwan
1983 Singapore
1983 Bahrain
1983 Saudi Arabia
1983 Oman
1984 United Arab Emirates
1987 South Korea
1989 Indonesia
1998 Thailand
1999 Malaysia
2003 China
2003 Kuwait
2003 Qatar
2007 The Philippines
2008 Egypt
2012 Vietnam
Taiwan
The number of cases sold
around the world in FY 2012
Nutraceutical Business
ORONAMIN C DRINK:
‘Full of Vitality!’
‘Genki Hatsuratsu!’
For decades ORONAMIN C DRINK has been an iconic
beverage in Japan with the widely recognized
advertising catch copy ‘Genki Hatsuratsu!’ (‘Full of
Vitality’). The product’s development dates back over
half a century to 1961.
The pursuit of a great-tasting nutritional drink, the
development idea of which was to add carbonation,
resulted in the creation of the enduringly popular
ORONAMIN C DRINK. Today, 48 years on from its 1965
launch, ORONAMIN C DRINK is still contributing to
the maintenance and improvement of people’s health
across generations and oceans. This has been the
outcome of continuous innovative initiatives since the
product was created nearly half a century ago.
Aiming for a GreatTasting Carbonated
Nutritional Drink
When ORONAMIN C DRINK
(ORONAMIN C below) was
created in the 1960s, medicinal drinks had established a
large market in Japan. Into
that market, Otsuka Pharmaceutical launched a series of
medicinal drinks (Glucuronic
Acid Vitamin Drink,
King Shiro, and Queen Shiro)
but they faced an uphill
battle. And so, the company
considered developing a new
product – a great-tasting,
carbonated nutritional drink.
The addition of carbonation
was the key to being innovative at that time. Further, it
developed the product as a
soft drink that could be sold
in general retail shops instead of as a medicinal drink.
With the hope of making
it popular among a broad
audience, it was named in
part after one of Otsuka’s first
flagship products: Oronine
Ointment. ‘Oron’ from Oronine Ointment was combined
with ‘amin C’ from vitamin C,
of which there is a lot in the
product, to create the name
ORONAMIN C.
The aspiration to create a
great-tasting nutritional drink
was reflected in the label
design. With the circular,
bright red symbol mark
printed on the label to make
it stand out, the product was
designed to bring the concept
of nutrition into everyday
life in Japan, which at that
time was experiencing rapid
economic growth.
Full of Vitality
across the
Generations
Commitment to
Safety
While the originally developed taste has remained the
same, the bottles have been
continually improved so that
customers can enjoy the
drink more safely and conveniently. For example,
the original crown cap was
changed to a screw cap
so that the bottle could be
opened without a bottle
opener. In April 1986, out of
consideration for customers’ safety and health, it
was changed to a maxi cap
so that the bottle could not
be recapped once opened.
This change was completed
in about six months. Distributors and customers have
praised the company for
its customer-first approach
and the way it takes action
quickly.
The maxi cap itself has
changed: from tin plate, to
soft aluminum, to the current
version in which the ring is
made of 3D plastic, evolving to be safer and easier to
open. Otsuka Pharmaceutical
was the first to adopt the
cap with a ring made out
of plastic.
While carrying out safety
and reliability initiatives
for ORONAMIN C, Otsuka
Pharmaceutical has also
developed numerous ad campaigns in step with the times.
This has always kept the
brand fresh: cumulative sales
in Japan since 1965 reached
30 billion bottles in 2011.
Every year the company sells
over 500 million bottles of
ORONAMIN C, one of Japan’s
iconic beverages.
Even now, 48 years after its
launch, ORONAMIN C is a national drink that enjoys wide
popularity. It has grown into a
brand that wins new customers by being handed down as
a familiar beverage from parent to child and from child to
grandchild across the generations. ORONAMIN C has been
developed by the Otsuka
Group, including Otsuka
Chemical Co., Ltd., over many
years. From here on, Otsuka
Pharmaceutical will continue
to develop the product with
consistent initiatives from
production through marketing to deliver the energy
boost of ORONAMIN C to
as many people as possible,
both in and outside Japan.
July 3: ORONAMIN C Day
Otsuka Pharmaceutical has designated July 3 as ‘Nami Day’
(a word play on the product name and also on the pronunciation
of July 3 in Japanese) to celebrate ORONAMIN C. On this day all
employees across Japan in the Nutraceuticals Division focus on
delivering the energy boost of ORONAMIN C.
Á
Full of Vitality
across the Oceans
ORONAMIN C has been
sold since 1985 in six Middle
Eastern countries – Bahrain,
Kuwait, Oman, Qatar, Saudi
Arabia and the United Arab
Emirates (UAE.) In the UAE,
the drink’s popularity has
grown to the point where it
is practically a national drink.
Supermarket shelves are
packed with ORONAMIN C in
cities across the Middle East.
A poster for ORONAMIN C DRINK
in Middle Eastern countries
30 31
Nutraceutical Business
Baked Soy Bar
SOYJOY
SOYJOY is a new type of nutritional
food that contains no wheat and is
baked using whole soybean flour
along with several other ingredients.
SOYJOY provides all the nutrition of
soybeans including vegetable protein
and soy isoflavones in a great-tasting
snack. It is also has a low glycemic
index (GI), which means the sugars
are absorbed slowly, making weight
gain less likely. Not crumbly, SOYJOY
is a smart and delicious way to enjoy
the nutritional benefi ts of soy.
New Soy Products,
New Solutions:
Soylution
Based on the concept of ‘Soylution’ – that soy can provide
solutions to human health and environmental issues –
Otsuka Pharmaceutical has been developing new forms of soy
products that offer delicious new ways for people around
the world to enjoy benefits from whole soy nutrition.1
The first Soylution product was the baked soy bar SOYJOY.
Launched in 2006, it is now sold in 11 countries and regions
around the world, including in the U.S., Asia, and Europe.
Two research institutes in Tokushima have also developed the
sparkling soy water SOYSH and the healthy soy snack
SoyCarat for global markets. Otsuka is committed to
contributing to the health of people worldwide by inventing
new ways to enjoy soy and working to raise awareness
of the high nutritional value and potential of soy.
Healthy Soy Snack
SoyCarat
SoyCarat is a snack food made mainly
of whole soy. Each packet of SoyCarat
is made with approximately 50 soybeans. SoyCarat provides the nutrition of soy with the enjoyment of a fun
rattling sound when shaken. Calories
have been kept down to about 120
calories per bag as the snack is baked,
not fried. Everyone from children to
adults can enjoy SoyCarat.
SOYJOY Peanuts Wins
Great Popularity
In April 2013, Otsuka
Pharmaceutical launched
a new product: SOYJOY
Peanuts. The first product to
be made without dried fruit,
SOYJOY Peanuts combines
the satisfying flavor and
texture of crunchy peanuts
with a delicate sweetness.
SOYJOY Peanuts quickly
became a hit among a wide
range of customers, especially business people.
The brand concept behind
SOYJOY is ‘ to enable
customers to enjoy choosing
soy.’ SOYJOY products make
the nutrition of soy easily
accessible even for busy
people, with tasty flavors
for everyone. The market is
enthusiastically welcoming
this concept.
Sparkling Soy Water
SOYSH
SOYSH contains the nutrition of whole
soybeans (excluding the thin outer
peel), including the okara (or soybean
fiber) which gets lost in soy milk. It
is a refreshing carbonated beverage
with no unpleasant soy aftertaste.
One bottle contains a single serving
of 100 ml, which is just right for a daily
health boost.
Tamaura
Settlement,
Okushiri Island,
Hokkaido
In the early 20th century, 25 brides
came to this island. Most of the
islanders ate fish. In one community, a settlement called Tamaura,
the women who came as brides
cultivated the land and ate soybeans. Soon this community was
the longest lived on the island.
Eating soy, a vegetable protein led
to long life.
Eating Soy –
Nutrition for Longevity
1
Excluding the thin outer peel
World’s Longest
Life Expectancy
World’s Highest
Consumption
of Soy
The life expectancy
in Japan is 83 years,
the longest of the world’s
194 countries.
Japanese people
have the highest annual
per capita consumption
of soy.
2
FAOSTAT Food Supply
3
National Health and Nutrition
Survey, Ministry of Health, Labor
and Welfare
4
According to Prof. David Pimentel
of Cornell University (the U.S.)
32 33
To live a long life in good
health is a basic human
hope. Soy, an integral part
of Japan’s traditional food
culture, has potential as a
solution for the world’s health
and environmental issues.
Today, the high nutritional
value and potential of soy is
attracting the attention of
the world’s researchers.
One finding is that soy may
promote longevity, as shown
in the WHO-CARDIAC Study,
an international collaborative
research study on cardiovascular disease and nutrition
that the World Health Organization conducted.
Japanese people, who have
the longest life expectancy
in the world, eat the greatest amount of soy, at 8.19kg
annually per capita.2 Most
Japanese bean consumption comes from processed
soy products (e.g., tofu and
natto). In recent years, however, soy consumption by
people aged 40 or younger
has tended to be below the
average consumption due to
skipping breakfast and the
westernization of diets.3 No
more than 6% of soybeans
grown worldwide are eaten
directly by people.
It takes 10kg of soybeans or
other grains to produce 1 kg
of beef, which is one source
of protein. The production of
soybeans only needs 1/50th
of the water and 1/20th of
the energy that is consumed
in the production of beef.4
If more people could eat
soy directly, with the world
population expected to top
nine billion by the year 2040,
it would represent a major
step toward the resolution of
both health and environmental issues.
Nutraceutical Business
Nature Made, the No. 1
National Vitamin Brand
in the U.S., Keeps Growing
Nature Made
Pharmavite LLC, founded
in California in the U.S. in
1971, started marketing
Nature Made products in
1972 when the vitamin, mineral and supplements market
was in its infancy. More than
40 years later, the original
Nature Made commitment is
unchanged: ‘to provide highquality vitamin and mineral
supplements at an affordable
price.’ The United States
Pharmacopeia (USP), which
is a globally used quality
standard, certifies the quality
of many of the Nature Made
products. Today, Nature Made
is the number one vitamin
brand in the U.S.1
Pharmavite has been a
leader in the U.S. supplement
industry by pioneering new
segments such as for vitamin
D and fish oil and releasing
timely research results on
the health improvement
effects of vitamins and other
supplements. Pharmavite
has also strengthened the
Nature Made brand by providing pharmacists, nutritionists, and consumers with
the latest nutrition-related
information. Nature Made
has been the number-one
national vitamin brand sold
in U.S. stores for six consecutive years1 and has
recently been chosen as the
number-one, pharmacistrecommended brand in eight
categories.2 At present,
Nature Made is available
in 10 countries and regions.3
Japan
Launch of Super Vitamin D,
Containing the Daily Optimum Dose
of Vitamin D in a Single Tablet
United States
New Plant Established
in Alabama
Americans today recognize
the need to take good care of
themselves, and they seek to
stay well and be as healthy
as they can. This has driven
growth in the vitamin, mineral, and supplements market,
which has nearly tripled since
1995.4 In this context, Pharmavite built a new dietary
supplement plant in Opelika,
Alabama in the Southeastern
U.S. as a second production
base, adding to the California
plant in the west. The new
plant started operations in
January 2013.
In June 2013, an opening
ceremony was held at the
new plant with the local U.S.
congressman, the governor of Alabama and other
dignitaries in attendance.
Pharmavite is positioned for
future growth by expanding
production and providing
even more consumers with
high-quality products.
Contributing to Health through
Japan-France Collaboration
Nutrition & Sante SAS
Nutrition & Sante SAS (N&S)
is a health and nutritional
food company headquartered
in the south of France whose
products are available in
over 40 countries, mainly in
Europe. N&S, whose name
literally means ‘nutrition and
health,’ oversees 25 brands
in the health food field. It has
an approximately 60% share
of the French market for
functional foods and nutritional foods. N&S joined the
Otsuka Group in 2009 as the
production and marketing
base of nutraceutical products in Europe.
Otsuka Pharmaceutical is
currently introducing N&S’s
leading brands – Gerblé,
the top health food brand in
supermarkets in France, and
Gerlinéa, the top diet brand
in French supermarkets1 – to
Japan. Meanwhile, N&S has
started marketing SOYJOY
in four European countries.
Capitalizing on their respective strengths, the two companies are making the most
of their Japan-France business collaboration.
France
Japan
Strengthening
Position in
Gluten-free Foods
Bringing French
Health Foods to
Japanese Tables
In December 2012, N&S
acquired Valpiform from the
multinational dairy conglomerate, Lactalis Group. Established in 1990, Valpiform is a
pioneer and French leader in
gluten-free and allergen-free
nutrition. N&S has commissioned Valpiform to manufacture gluten-free products
since 2007, and its acquisition
now gives N&S an integrated
organization for the development, production, and sale of
gluten-free products.
In Japan, Otsuka Pharmaceutical markets the Gerblé
and Gerlinéa brands under
the concept of the ‘French
Dietetic Secret’ for consumers to maintain health while
enjoying eating. The French
marketing method has been
adopted in Japan for N&S
products – the entire Gerblé
and Gerlinéa series are
displayed on their own
shelves separate from competitor products, rather than
sharing a shelf with other
products within the same
category. This unique retailing technique invites customers to select from a delightful
range of products, as well as
expanding brand recognition.
In October 2012, the company
launched a new item from
Gerblé, Poppy Seed &
Lemon Biscuits, and in March
2013 it launched Gerlinéa
meal replacement bars in
white chocolate and orange
chocolate flavors.
France
1
IRI Value Share of market –
nov 2012
34 35
Japan
Pharmavite joined the Otsuka
Group in 1989, and it has
been 20 years since Otsuka
Pharmaceutical introduced
the Nature Made brand in
Japan in 1993. The company
has gradually expanded the
lineup on offer in Japan;
today it markets 61 products
in 36 categories. In October
2012, it launched Super
Vitamin D, making it easy for
people to get the optimum
dose with a single daily
tablet. Going forward, Nature
Made products will continue
to support the health of the
public by making good nutrition easy to obtain for people
enjoying today’s diverse
lifestyles.
1
Pharmavite calculation based in part
on data reported by Nielsen through
its Scantrack® service for the Dietary
Supplements category in dollar and
unit sales, for the 52-week period
ending 12/29/2007 and 12/28/2008 in
US Food Drug Mass channels; and for
the 52-week period ending 12/26/2009,
12/25/2010, 12/24/2011 and 12/22/2012 in
US xAOC channels. ©2013 The Nielsen
Company
2
Based on US News & World Report Pharmacy Times Survey
3
U.S., Japan, Mexico, South Korea,
Taiwan, Hong-Kong, Iran, UAE,
Iraq, Kuwait
4
“Supplement Business Report”
(2004 and 2012 editions),
Nutrition Business Journal
Nutraceutical Business
Helping People Around the World
to Realize the Dream of Healthy, Beautiful Skin
Cosmedics –
A Breakthrough Business
Cosmetics
+ Medicine
=
Human skin comprises approximately 16 % of a person’s
total body weight and is the
largest organ of the human
body. Committed to contributing to overall health, Otsuka
Pharmaceutical took on
the new challenge of skin
health in 1990, leveraging its
expertise in pharmaceutical
research.
To do so, it established
the Otsu Skin Care Research
Institute on the shores of
Lake Biwa and started original
research on skin physiology
using equipment that can
simulate global weather
conditions throughout the
seasons.
The results of that research
led to the launch of two
brands: InnerSignal in 2005
and UL•OS in 2008. Each of
these brands offers a line of
innovative products shaped
by sincere caring for customers. They use new methods
to reach new markets and are
rapidly providing new satisfaction.
The cosmedics business is
led by a young female
senior operating offi cer
Otsu Nutraceuticals Research Institute
16%
2
UL • OS Total Skincare Brand for
Men Creates New Market among
Middle-aged Men
The UL• OS brand is a total
body skincare line-up for
men with products to vitalize
everything from head to toe.
Since its launch in 2008, the
lineup has been expanded,
with sales and recognition
also increasing. With the provision of samples and product explanations when and
where users actually want to
use them, the brand is now
driving the burgeoning men’s
cosmetics market.
36 37
As a part of its constant effort
to reach new consumers,
Otsuka Pharmaceutical
released a new sunscreen
in February 2013. In South
Korea, where the UL• OS
brand debuted in 2012, the
company is trying to improve
recognition through unique
approaches such as promotions using social media. A
major Korean drugstore chain
has picked up the brand, and
expectations are very high.
InnerSignal Achieves High Rate
of Repeat Users: Brand Loyalty Grows
Via Direct Marketing
Energy Signal AMP (adenosine monophosphate), has
obtained approval in Japan
as a quasi-drug with new
effects and efficacy for skin
lightening. InnerSignal, which
contains Energy Signal AMP
as an active ingredient, was
launched in 2005 and ever
since has been responsive
to many women’s concerns
about their skin. After Otsuka
Pharmaceutical switched to
a new distribution channel,
adopting a direct marketing
strategy, InnerSignal sales
have continued to grow
strongly as the brand earns
new fans.
Aspiring to create a brand
that is an integral part of
women’s daily lives, Otsuka
Pharmaceutical will work on
building trust with customers
through careful communication. The goal is to make
InnerSignal a brand loved by
as many women as possible.
Direct marketing
business leader
International
OIAA: Otsuka’s Integrated Organization
for Asia and the Middle East
From East to West:
Global Expansion from Asia
The Otsuka Group has business locations in 26 countries
and regions around the world, and Otsuka Pharmaceutical’s
products are available in more than 80 countries. Starting in
the wind-swept Pacific coast of Tokushima, Otsuka’s presence
gradually spread throughout Japan, then to Asia, and then
worldwide. With a gaze on the horizon and business practices
influenced by Tokushima’s artisanry and respect for diversity,
Otsuka Pharmaceutical aims to help people everywhere
to lead healthier lives.
In 2001, Otsuka Pharmaceutical created the Otsuka International Asia / Arab (OIAA) Division to establish a more scalable
business in Asia and the Middle East by operating Otsuka
Group companies across the regions in an integrated fashion.
Today, the OIAA Division manages over 30 companies in
15 Asian and Middle Eastern countries and regions, where it
offers pharmaceuticals, medical devices, nutraceuticals,
cosmedics, and other highly original products.
The expansion of Otsuka’s
pharmaceutical business
into Asia and the Middle
East began in 1973, with the
establishment of Thai Otsuka
Pharmaceutical Co., Ltd.
and its I.V. business. Then in
1974, P.T. Otsuka Indonesia
and Taiwan Otsuka Pharmaceutical Co., Ltd. were
established, followed by
Arab Otsuka Pharmaceutical
Co., S.A.E. (currently Egypt
Otsuka Pharmaceutical Co.,
S.A.E.) in 1977.
In 1981, China’s Ministry of
Health decided the country
needed a production base
for quality I.V. solutions.
Subsequently, Otsuka was
invited to fulfill this need and
became the first Japanese
pharmaceutical company to
establish a joint venture in
China – China Otsuka Pharmaceutical Co., Ltd. Today,
Otsuka (China) Investment
Co., Ltd., which oversees
Otsuka’s pharmaceutical
business in China, is investing for a vibrant, long-term
presence, which already
includes pharmaceutical
research institutes in Beijing
and Shanghai.
Staff members of Otsuka (China) Investment Co., Ltd.
The 2nd POCARI SWEAT plant, P. T. Amerta Indah Otsuka
(Kejayan Factory)
Otsuka Pharmaceutical Affiliates around the World
Number of Employees
28,000
Outside of Japan
20,000
Asia / Arab
12,300
North America
4,200
Europe
3,600
(70 % of total employees)
as of March 2013, numbers are approximate
The 2013 OIAA Area Managers Meeting
38 39
Otsuka Welfare Clinic:
A Decade of Free Medical Care for
Afghan Refugees in Pakistan
Otsuka Group companies
across Asia and the Middle
East established the Otsuka
Welfare Clinic in 2003 to
provide free medical care for
Afghan refugees in Peshawar,
Pakistan.
These refugees faced critical
shortages of food, clothing
and housing in refugee camps
in the city of Peshawar near
the Afghanistan-Pakistan
border. The need for a medical clinic was clear. More than
700,000 people have visited
the clinic since its establishment 10 years ago, and approximately 150 patients still
visit every day.
The clinic also sees nearby
residents in addition to people from the refugee camps,
helping to lighten the load on
medical facilities in the area.
10th
A nni ver s ar y
In 2011, the Japanese Ambassador to Pakistan bestowed a
certificate of commendation
on the Otsuka Group, citing
its outstanding contributions
to community welfare and
goodwill between Japan and
Pakistan through medical
activities.
A doctor and patient
at the Otsuka Welfare Clinic
700,000
Number of patients in 10 years
New Pharmaceutical Sales Venture
Established in Turkey, Where Eastern
and Western Cultures Meet
A New Challenger in the
Growing Vietnamese Market
Ceremony to mark the establishment
of Abdi Ibrahim Otsuka Pharmaceutical
Company
40 41
In October 2012, Otsuka
Pharmaceutical and the
leading Turkish pharmaceutical company Abdi Ibrahim
each invested a 50 % stake to
establish a new joint venture,
Abdi Ibrahim Otsuka
Pharmaceutical Company,
in Istanbul, Turkey, a nation
known as a meeting place of
European and Asian cultures
through the ages. The new
company will market Otsuka
Pharmaceutical’s innovative
pharmaceuticals in Turkey,
one of the world’s top-20
drug markets. Abdi Ibrahim
has been in the healthcare
business for more than a
century and the joint venture
is built on the licensing
partnership for Otsuka products the two firms forged
over the last decade, reflecting a shared, long-term
orientation.
The venture will introduce
to patients and physicians
throughout Turkey a wider
range of first-in-class Otsuka
pharmaceuticals that have
been well-received elsewhere
in the world. The two companies will leverage their
unique abilities and experience while collaborating as
equal partners, a defining
feature of all Otsuka
partnerships.
In 2012, Otsuka Pharmaceutical established Otsuka Thang
Nutrition Co., Ltd., a joint
venture tasked with marketing POCARI SWEAT and other
consumer products in Vietnam. Marketing of POCARI
SWEAT began in earnest in
2013 in supermarkets, convenience stores, local markets, and other locations.
Vietnam is experiencing
rapid economic growth, with
one of the largest populations
in Southeast Asia and more
than 60% of Vietnamese in
their 30’s or younger. The
company is aiming to build
product recognition and
understanding of the POCARI
SWEAT concept and to
encourage people to try it
in order to increase repeat
users. Otsuka Pharmaceutical
is positioning POCARI SWEAT
as a beverage that can contribute to the health of the
Vietnamese people, seeking
to see the country become
another pillar of Otsuka’s
presence in Southeast Asia.
Diversity
Leading the Way on Diversity
Otsuka Pharmaceutical embraces diversity as a core
element of our dynamism. Fully engaging female and male
employees of different nationalities is one of the factors in our
innovation and success on the global stage.
Beanstalk Kids Center:
Offering On-site Daycare to Help
Employees Raise Children and
Grandchildren with Boundless Curiosity
In 2011, Otsuka Pharmaceutical opened an on-site daycare
facility, called the Beanstalk
Kids Center Tokushima, at the
birthplace of the company
in Japan. The facility, which
has a capacity of 100 children
from infancy to 6 years old,
is for the children and grandchildren of employees.
The name was taken from
the English folktale, ‘Jack and
the Beanstalk,’ based on a
desire to help children grow
up strong and energetic, just
like the fabled beanstalk.
Tokushima cedar is used in
the central court called Jack’s
Hall, from which the surrounding rooms branch out,
an arrangement that brings
to mind the branches of a
beanstalk.
The center is currently building an extension to accommodate up to 150 children.
The company is also constructing a second on-site
daycare facility at its Osaka
Headquarters that is scheduled for completion in 2014.
‘ Facilitating the growth
of children by letting their
wonderful talents and
individuality shine…’
Age 0 – 6
An image of the
Beanstalk Kids Center Osaka
Jack’s Hall
The Beanstalk Kids Center Tokushima
Five Female Operating Officers:
A Top-tier Rate of 11.4% Women in
Senior Management
Aiming to actively promote
women, Otsuka Pharmaceutical started the Women’s
Forum (now called the
Diversity Forum) in 1990.
The company has been
a pioneer of programs that
support women’s diverse
life stages, such as childcare
leave, which is taken by
100% of female employees
following childbirth.
At present, Otsuka Pharmaceutical has five female
operating officers, out of
a total of 44 executive directors and operating officers.2
That is 11.4%, which greatly
exceeds Japan’s 1.2%3
national average.
These women operarting
officers manage operations
as diverse as human resources, public relations, international pharmaceuticals,
ophthalmology and dermatology, and cosmedics.
Otsuka Pharmaceutical President
Says Women and Young People
Bring Innovation
‘What can we do in Japan
in order to stimulate the
economy through the promotion of gender equality in
the workplace?’
This was a topic that drew
attention at the Health Policy
Summit 2013 held by the
Health and Global Policy
Institute. Otsuka Pharmaceutical President Taro Iwamoto,
who participated in the panel
discussion, said that gender
empowerment1 would not be
realized just by waiting for
systems to change.
42 43
He said, ‘Women and young
people can facilitate change
in Japanese corporate
culture. Precisely because
they are not constrained by
the existing system, they can
come up with ideas that
men would not.’ He also
explained that, ‘What is lacking in Japan is leadership.
Rather than endless debate
on specific women’s issues,
we need to address the
overall problem of how to
recruit and develop global
leaders – whether women or
men – who can pursue the
innovation needed to drive
social and business growth.’
Panelists in the Health Policy Summit 2013
February 2013
From left:
Hiromi Murakami
Assistant Professor, National Graduate Institute for Policy Studies
and Executive Director, Health and Global Policy Institute
Susan H. Roos
Wife of the U.S. Ambassador to Japan and employment attorney
Kimie Iwata
President, Japan Institute of Workers’ Empowerment and
advisor to Shiseido Co., Ltd.
Taro Iwamoto
President, Otsuka Pharmaceutical Co., Ltd.
Affiliations and titles
as of the time of the Summit.
1
Women becoming involved with
decision making through participation
in politics and economic activities.
2
Seven executive directors, three
auditors, and 34 operating offi cers
(as of June 6, 2013).
3
Based on data in White Paper on
Gender Equality 2011.
Five female operating offi cers
Hometown Tokushima
Tokushima, Japan:
Otsuka Pharmaceutical’s
Birthplace
A Workplace That Nurtures
Creativity and Inspires Diversity
and Change
Today, Otsuka Pharmaceutical’s products are
used in more than 80 countries, while the
figurative center for employees working around
the world is still in Tokushima, the birthplace
of the company. As a manufacturer born
and bred in Tokushima, Otsuka Pharmaceutical
works hand in hand with the people of Tokushima
to preserve its natural environment, hand down
its traditional culture, and spur community
development. Supported by Tokushima, the
company and its people learn and grow locally,
but have a global-scale aspiration to contribute
to the health of people everywhere. Otsuka
Pharmaceutical will always value its hometown
of Tokushima.
Human Resource
Development Institute:
A Place For Learning
to Question Common
Knowledge
Three monuments that
overturn stereotypes adorn
Otsuka Pharmaceutical’s
employee training center, the
Human Resource Development Institute established
in 1988. These monuments
were created to encourage
employees to study diligently,
make great leaps in the future
and reach their full potential.
Human Resource Development Institute
In the Tomato Hall at the Human
Resource Development Institute,
thousands of plump, red tomatoes
grow on only a few tomato plants
overlooking visitors. Each tomato
‘tree’ grows stalks stretching over
10 meters. However, these tomatoes
are not a special variety; they are a
common variety, merely grown using
hydroponic cultivation. Tomato plants
are usually grown in the ground. This
variety, planted in the ground, would
be no more than normal size. In other
words, the ground (soil cultivation)
seems to have many growth-inhibiting
factors, limiting the tomatoes’ growth
from reaching their full potential.
Our Hometown
TOKU
SHIMA
‘In order to change preconceptions,
we planted the giant tomato tree.
Normally, a tomato plant produces
only 50 to 60 tomatoes, but if you alter
the way you cultivate it, it has the
potential to produce 10,000. Likewise,
if people think a little differently,
they could unlock their enormous
potential.’
Located inside the entrance to Vega
Hall is a bent giant cedar with
another cedar lying atop it, appearing
unsteady at first glance, but maintaining magnifi cent balance. Here,
a giant cedar, which is not supposed
to be bent, is bent, and two logs
that should not be stable with one
atop the other are holding steady at
a single point. This untitled work
conveys a constant message about
breaking down stereotypes and
changing our thinking.
In this stone garden, large, heavy
stones that should not float do
appear to float on the water. One is
even floating above strong fountain
waters. The gently curved stones
represent Otsuka Pharmaceutical’s
spirit — its love of humanity and its
wish for people’s well-being.
This garden, which grabs people’s
interest, enriching the heart and
giving them the ability to think about
things, encourages them to come up
with new ideas.
Tatsuya Ishii
24th Free Rock Concert
Held at Otsuka’s Factory
Contributing to the
Community
through Soccer
Every year since 1990, the
year after it was established,
the Tokushima Wajiki Factory,
which manufactures Calorie
Mate and pharmaceutical
products, plans and holds a
free outdoor concert with
the cooperation of local
authorities. The concert is
held during the Awa-Odori
Dance Festival every summer. In 2013, five musicians
including Tatsuya Ishii and
BENI gave inspiring performances for the many families
and young people who
gathered on the lawn in front
of the stage. The concert
has become a major annual
event, and about 200 Otsuka
Pharmaceutical employees
volunteer for it each year.
The Awa Dance –
Employees Help Hand Down
Tokushima’s Traditional Culture
and Share It with the World
Artwork by Mexican sculptor
Sergio Bustamante
There are a number of works of art
created by artists both in and outside
of Japan exhibited on the premises of
the Tokushima Wajiki Factory, inspiring employees of Otsuka Pharmaceutical to greater daily creativity.
44 45
Awa-Odori (Awa-Dance),
a choreographed dance
festival that draws well
over one million spectators
per year, has been a part
of Tokushima’s traditional
culture for over 400 years.
Otsuka Pharmaceutical,
established in Tokushima,
helps to hand down this
tradition. The company’s
employees participate in
ren (dance groups), a tradition started in 1988 with
the formation of the Otsuka
Ren, showing off their dance
moves every year during
the festival. Employees in
Tokushima, Osaka, and
Tokyo train strenuously under
instructors from famous
ren, and those who excel at
dancing and playing musical
instruments are selected to
perform at the festival.
The Otsuka Ren’s activities
are not limited to Japan.
Sparked by the global alliance formed with Denmark’s
H. Lundbeck A/S in 2011, in
April 2013, 44 members of
the Otsuka Ren performed at
the 6th Copenhagen Sakura
Festival (held in Copenhagen,
the capital of Denmark) at
the request of the Japanese
Embassy in Denmark.
Tokushima Vortis is a soccer
club in Japan’s professional
league, J. League. The club,
which emerged from a soccer
club at Otsuka, was established in 2004 in cooperation
with Tokushima city and prefectural authorities, aiming
to bring new vibrancy to the
region. It has been playing
in the J2 league since 2005.
The club is actively involved
in community contribution
activities in cooperation
with the Prefectural Board of
Education, including helping
to create the J. League’s first
supplementary reader for a
physical fitness textbook and
a food education program.
Sistine Hall
Otsuka Museum of Art:
Showcasing the World’s Art in Tokushima
The Otsuka Museum of Art,
an engaging museum exhibiting masterpieces reproduced
on ceramic panels, was
opened in Naruto, Tokushima
Prefecture, Japan in 1998
on the 75th anniversary of
the founding of Otsuka. The
museum displays many masterpieces of Western art, from
ancient murals to modern
works, from more than 190
museums in 25 countries.
Rendered with special technology developed by Otsuka
Ohmi Ceramics Co., Ltd.,
more than 1,000 pieces of
art are now reproduced in
original size, and their colors,
which will virtually never
fade, faithfully convey the
artistic essence of the original
works. In addition, the museum conducts a variety of
activities in cooperation with
the community, such as concerts and lectures, to foster
local culture and encourage
people to visit the museum.
First-of-Its-Kind
Museum in the World
Works of art cannot avoid
color fading and deterioration
over time, and in some cases
they are damaged by pollution, earthquakes, or fire.
One of the inspirations for
the creation of the museum
was the recognition that
ceramic panel reproductions,
with the ability to keep colors
and shapes unchanged for
more than 2,000 years, could
contribute to the recording
and preservation of cultural
assets.
The efforts include groundbreaking attempts such as
recreations of El Greco’s high
altar paintings, which were
dispersed in the Napoleonic
wars, and the reproduction of the closely-guarded
treasure Guernica by Pablo
Full-size Reproduction
of the Sistine Chapel Ceiling
Picasso, which has received
praise from Picasso’s son,
curators and museum staff
from around the world who
have visited Japan to view
the 1,000-plus works. The
museum displays, opposite
each other, reproductions
of Leonardo da Vinci’s The
Last Supper before and after
its restoration. In this and
other ways, the museum has
made numerous exhibits that
make the most of the special
qualities of ceramic panels
to create wonders that can
only be seen at the Otsuka
Museum of Art in Tokushima.
The Otsuka Museum of Art
is proud to have created the
world’s first museum of its
kind, which remains unique
in its conception and use of
technology.
Beginning in May 1508 and
finishing in only four years,
Michelangelo painted large
frescos on the ceiling of
the Sistine Chapel in the
Vatican at the behest of Pope
Julius II. Various scenes from
the Old Testament such as
the creation narrative from
the Book of Genesis are masterfully depicted across the
ceiling and onto the walls on
both sides. Even today countless visitors from around the
world make the pilgrimage to
the chapel to look up in wonder at these masterpieces.
The Sistine Hall in the Otsuka
Museum of Art is a full reproduction of Michelangelo’s
great work. However, the
ceiling spandrels that transition from the walls to the
ceiling in complicated curves
46 47
Reproductions of The Last Supper – before and after its restoration.
This is a photograph exhibited works at the Otsuka Museum of Art.
and other intricate curvatures
could not be reproduced on
ceramic panels when the
museum was first opened in
1998. Ahead of the museum’s
10-year anniversary, the
museum and Otsuka Ohmi
Ceramics set about using the
latest technological capabilities to create curved ceramic
boards, making it possible
to display the entire chapel
ceiling and wall paintings
for art lovers. The Otsuka
Museum of Art allows visitors
to appreciate the world’s art
in the original sizes without
leaving Japan. And within
the museum, the Sistine Hall,
which enables visitors to
experience the actual vastness of the real chapel, has
become a central, popular
space.
Since 2009, the Sistine Hall
has hosted new performances of kabuki based on the
concepts of collaboration
between Japan and the West
and the application of new
creativity to traditional kabuki
works. These groundbreaking
attempts at fusion art have
been very well received.
In March 2013, the Otsuka
Museum of Art marked its
15th anniversary. The museum devises ways to bring
Otsuka’s hometown of
Tokushima into greater contact with the wonders of
art and is determined to
continue popularizing art
culture and contributing to
the local community.
Otsuka Holdings
Generates Robust Growth
for Four Years Running
The Otsuka Group is a group of
global healthcare companies that
aim to contribute to the well-being of
people worldwide by creating original, innovative products recognizable
as uniquely Otsuka’s. The Group
seeks out the biggest challenges in a
wide range of health-related fields
to deliver on the promise of its
corporate philosophy, ‘Otsuka-people
creating new products for better
health worldwide.’
Otsuka originated as a manufacturer of raw chemical materials
established in Naruto, Tokushima
Prefecture in 1921. It later entered
the pharmaceutical business with I.V.
solutions. In the 1970s it embarked
on drug discovery and also began
its business outside Japan, in Asia.
Today, Otsuka operates a global
healthcare business that provides
diagnostics and treatments for
diseases and consumer products for
the maintenance of everyday health
in two core businesses: pharmaceuticals and nutraceuticals.
Following the establishment of
Otsuka Holdings Co., Ltd. in 2008,
the company has achieved growth in
both consolidated sales and operating income for four straight years.
The Otsuka Group marked its 90th
anniversary in 2011. Going forward,
the Group will continue to pursue
continuous growth by developing
innovative products and creating and
expanding new market categories,
true to Otsuka’s mottos of jissho
(‘proof through execution’), which
describes how the group tenaciously
converts original ideas into
successful products, and sozosei
(‘creativity’), which it practices by
questioning preconceived ideas.
Otsuka Holdings
Business
Overview
Group
Structure
Otsuka Holdings Co., Ltd.
Company name
Otsuka Holdings Co., Ltd.
Established
July 8, 2008
President and
Representative Director, CEO
Tatsuo Higuchi
Otsuka
Pharmaceutical
Co., Ltd.
Otsuka
Pharmaceutical
Factory, Inc.
Taiho
Pharmaceutical
Co., Ltd.
Otsuka
Warehouse
Co., Ltd.
Otsuka
Chemical
Co., Ltd.
Otsuka
Medical Devices
Co., Ltd.
Pharmaceutical Business
Clinical Nutrition Business
Nutraceutical Business
Soy Business
Capital
JPY 81.69 billion
Medical Device Business
Distribution
Other Business
Registered address
2-9, Kanda Tsukasa-machi, Chiyoda-ku,
Tokyo 101-0048 Japan
Tokyo Headquarters
Shinagawa Grand Central Tower,
2-16-4, Konan, Minato-ku,
Tokyo 108-8241, Japan
Financial
Information
Chemical
FY 2012
Net sales
1,218
Billion yen
FY 2012
Number of employees
70 (Consolidated: 25,330)
Operating
income
170
Billion yen
FY 2011
Group Companies
71 consolidated subsidiaries and
14 affiliates accounted for under the
equity method
Net sales
1,155
Billion yen
FY 2011
Operating
income
149
Billion yen
FY 2010
Business description
Control, management and related
activities with respect to the company’s
subsidiaries and affiliates active in
the pharmaceutical business,
nutraceutical business, consumer
products and other areas
Net sales
1,128
Billion yen
Net sales
1,084
Billion yen
Net sales
126
Billion yen
FY 2009
Operating
income
98
Billion yen
FY 2008
956
Billion yen
48 49
Operating
income
FY 2009
FY 2008
as of March 31, 2013
FY 2010
Operating
income
92
Billion yen
FY 2012
FY 2011
FY 2010
FY 2009
FY 2008
USD
in millions
USD
in millions
Net
sales
Operating
income
¥/$
12,951
14,048
13,561
11,654
9,755
1,804
1,809
1,519
1,058
934
94.05
82.19
83.15
93.04
98.00
Exchange rate
Otsuka Group celebrated its 90th anniversary
at the Otsuka Museum of Art in September 2011
90-year History of the Otsuka Group
1
2
3
13
14
15
1 Busaburo Otsuka, the Founder of
Otsuka, Riding a Cow
The Otsuka family was a farming family for
generations. Busaburo Otsuka, who would go
on to start the Otsuka Pharmaceutical
Kougyo-bu in 1921, used to help his father
Daitaro on the farm. He is shown here breaking
tradition already, riding a sacred cow.
2 Company Founder Busaburo Otsuka (right)
and his eldest son Masahito Otsuka. Masahito
went beyond his father’s wishes by expanding
the business nationwide and starting the
I.V. solution business.
4
16
5
6
7
8
9
10
11
12
17
18
19
20
21
22
23
24
5 Otsuka Pharmaceutical Factory launched
Otsuka’s first over-the-counter drug
Oronine Ointment in 1953. This long-seller,
still available today, made its mark using
innovative advertisements on vehicles, TV
and radio, as well as free samples.
6 Taiho Pharmaceutical Co., Ltd., was established
in 1963, following the Otsuka Chemical Co.,
Ltd. It in-licensed an anti-cancer agent from the
former Soviet Union and developed the world’s
first oral anti-cancer drug, making Otsuka a
leader in cancer treatment.
3 A saltpan of the time. Initially, Otsuka produced
chemical feedstock from saltpan residue.
This business was taken over by Otsuka
Chemical, established in 1950, and provided the
world with quality chemical feedstock and
pharmaceutical intermediary material.
7 Otsuka Chemical Co., Ltd. launched
Oranamin C Drink in 1965. It virtually became
Japan’s national beverage thanks to
high-impact ads like those featuring Japanese
comedian and actor Kon Omura and other
unceasing marketing efforts. In 2011,
the 30-billionth bottle was sold.
4 Busaburo Otsuka had to deal with many
defective products, pushing his family to the
brink of ruin. He overcame the crisis and left
behind these thoughts: ‘Quality is the lifeblood
of the factory. Packaging is a part of
quality. Make and sell products as if you were
the buyer.’
8 In 1968, Otsuka Pharmaceutical Factory, Inc.
introduced plastic bottles as containers for
I.V. solutions, a first for Japan. The company
went on to become a best partner in clinical
nutrition through a series of container
innovations and the development of new
I.V. solutions.
9 Inspired by the ready-to-eat meals carried
by soldiers, in 1968 Akihiko Otsuka launched
BON CURRY, the world’s first commercially
available food in retort pouches, through
Otsuka Foods Co., Ltd.
10 In 1970, Otsuka acquired capital in Earth
Chemical Co., Ltd. This company accelerated
development of a cockroach trap Gokiburi Hoy
Hoy and other new products and went on to
become Japan’s largest pesticide manufacturer.
11 Otsuka Pharmaceutical Co., Ltd. established
its own factory to produce non-I.V. end
pharmaceutical products in 1970 and its
own drug research institute in 1971.
12 In 1976, Akihiko Otsuka was appointed
president of Otsuka Pharmaceutical Co., Ltd.
and Otsuka Foods Co., Ltd. He greatly developed
the pharmaceutical, nutraceutical and foods
businesses by focusing on original products.
13 The boundless potential of the carbostyril
structure was recognizable at a glance to
an Otsuka researcher. In 1980, Otsuka
Pharmaceutical Co., Ltd. launched its first new,
originally-developed drug.
14 POCARI SWEAT was launched in 1980.
Unconventional features such as the
barely-sweet taste and blue package (a taboo
for beverages at the time), created a huge
market for electrolyte replenishment beverages
in Japan.
15 Rokuro Harima invented Oranamin C Drink
and presided over the development of
POCARI SWEAT and Calorie Mate.
16 Hi-Z Tower (the central research building) was
constructed in 1983. The ceramic panel mural
on the front of the building was created by
painter Taro Okamoto and named Inochi Odoru
(Life Leaping) by Buddhist nun and writer
Jakucho Setouchi.
17 ‘We planted giant tomato trees to get people
to notice the obstinacy of preconceptions...
Please dispel your preconceptions about the
people around you.’ Akihiko Otsuka at the
opening ceremony for the Human Resource
Development Institute, 1988.
18 In 1998, a one-of-a-kind museum displaying
masterpieces on ceramic panels was opened to
commemorate the Otsuka Group’s 75th
anniversary. On the occasion of the museum’s
10th anniversary, Pope Benedict XVI bestowed
the Pontifi cal Order of Pope St. Sylvester on
Akihiko Otsuka, director general of the museum.
19 Otsuka Pharmaceutical’s best-in-class
antipsychotic drug ABILIFY has received wide
praise for its effi cacy and safety.
20 Globalization of the I.V.solution business,
which achieved initial success in Asia,
accelerated around the beginning of the 21st
century. Ichiro Otsuka (right), the president
of Otsuka Pharmaceutical Factory, Inc. in
negotiations on a business alliance.
21 Otsuka is venturing into the rapidly-innovating
medical device field.
22 Otsuka Pharmaceutical Co., Ltd. is developing
globally appealing soy products based
on the concept of ‘Soylution’ – that soy can
provide solutions to human health and
environmental problems.
23 Otsuka Holdings was listed on the First Section
of the Tokyo Stock Exchange in December,
2010. There were ten employees when the
company was founded in 1921. Today, the
Otsuka Group employs approximately 42,000
people1 in 158 companies around the world
(as of March 2013).
24 In November 2011 the company signed a
global alliance agreement with the Danish
company H. Lundbeck A/S in order to provide
patients with a new generation of CNS drugs
refl ecting the latest science. In 2013, the
first drug to emerge from this alliance, Abilify
Maintena, was launched in the U.S.
1
Number of Otsuka Group employees
(including at non-consolidated companies)
Entering Another New Field
Otsuka
Medical Devices
Achieva Medical Limited
(Shanghai, China)
Development and marketing of coils
to treat cerebral aneurysm
More integrative approaches to healthcare have
become necessary as societies age. This is evidenced
by growing demand for minimally invasive disease
treatments and diagnostics, often combining a drug
treatment and a physical device.
In February 2011, the Otsuka Group established
Otsuka Medical Devices Co., Ltd., to aggressively
pursue business expansion by developing innovative
medical devices and business tie-ups in this area, thus
adding to its mainstay pharmaceutical business.
Specifically, Otsuka Medical Devices is pursuing the
development of treatments and diagnostic tools.
In the first area, the company is working on various
therapeutic instruments for the fields of cardiovascular
and gastrointestinal disease and orthopedics. In the
second, it is developing a self-propelled colonoscope
with a light burden on patients. Otsuka Medical
Devices is committed to contributing to the health of
people worldwide through the development of
innovative medical devices.
MicroPort Scientific Corporation
(Shanghai, China)
Development and marketing
in China of intervention products,
focusing on drug-eluting stents
KiSCO Co., Ltd.
(Kobe, Japan and Lyon, France)
Development and marketing of
products in the field of orthopedics
JIMRO Co., Ltd.
(Takasaki, Japan)
Manufacture and marketing of
Adacolumn, an adsorptive granulocyte
apheresis column used for treating
inflammatory bowel disease and
refractory skin diseases in 14 countries
Era Endoscopy S.r.l.
(Pisa, Italy)
Development of the Endotics
self-propelled colonoscope
50 51
A California Winery Known
for Some of the World’s Top Wines
Ridge Vineyards
Ridge Vineyards, a pioneering
California winery in the noninterventionist approach to
winemaking, has offered
exceptional, single-vineyard
wines under the Ridge name
since 1962. However, the
winery has a longer history
that started with a San Francisco physician purchasing
land near the top of Monte
Bello Ridge and then planting
vines and building the historic
winery in 1886.
Ridge’s winemaking approach
emphasizes traditional
methods, drawing on natural processes as much as
possible in both grape cultivation and winemaking. Paul
Draper, Ridge’s extraordinarily talented chief winemaker,
learned traditional winemaking in Italy and France.
Since then, for over 40 years
he has continued to craft
standout wines that are
extremely well-balanced and
age superbly.
Ridge’s renown is not limited
to the U.S.; it is well known in
Europe and elsewhere. Ridge
has continued to win praise
as a winery that consistently produces some of the
top wines in the world. In
Fate led to Ridge Vineyards coming under the umbrella of the Otsuka Group in 1986.
One anecdote tells the story like this: When the up-and-coming executive Akihiko
Otsuka told his father Masahito that he wanted to purchase Ridge Vineyards,
his father was outraged, saying ‘It is absurd for a company in the health business to
buy a company that sells alcohol!’ But Akihiko quoted the old saying, ‘sake (alcohol)
is the chief of all medicines,’ and persuaded his father to approve the deal.
2000, Draper was selected as
Man of the Year by the UK’s
Decanter magazine, one of
the wine world’s authoritative
awards.
Another spectacular achievement came in 2006. In that
year a rematch was held for
the legendary Judgment of
Paris, which rocked the world
of wine in 1976 and pushed
California wine into the world
limelight. The same as 30
years earlier, American reds
were pitted against French
Bordeaux reds, all made in
the early 1970s, in blind tastings by leading wine authori-
ties held simultaneously on
both sides of the Atlantic.
Shining in first place, far
ahead of a distant second,
was Ridge’s flagship wine,
the Monte Bello 1971. After
aging beautifully, Ridge wine
showed the world that it
could surpass the five best
Boudeaux Châteaux.
At present, Ridge wines are
exported to 45 countries and
widely recognized as wines
with world-class quality and a
top record as leading American wines. This is why they
frequently appear in diplomatic banquets for heads
of state. In June 2013, the
Geyserville 2008, a zinfandel
red wine, was served at a
dinner party hosted by U.S.
President Obama for Chinese
President Xi Jinping at the
White House.
Since 2008, Ridge has been
expanding its Monte Bello
vineyards, which will add
approximately 10 hectares
when all the vines are
planted. The new vineyard is
called Rousten Ranch, named
after a man who used to
grow grapes at that location.
Paul Draper
Otsuka main brands supported by 42,000 * Otsuka-people
Number of Otsuka Group employees (including at non-consolidated companies)
Otsuka Group
158 companies (including at non-consolidated companies)
in 26 countries and regions
U.S.:
Otsuka Pharmaceutical
Development &
Commercialization, Inc.
Otsuka Maryland
Medicinal Laboratories, Inc.
Otsuka America, Inc.
Otsuka America Pharmaceutical, Inc.
Pharmavite, LLC
Ridge Vineyards, Inc.
Cambridge Isotope Laboratories, Inc.
Crystal Geyser Water Company
Otsuka America Manufacturing, LLC
CIL Isotope Separations, LLC
Soma Beverage Company, LLC
Membrane Receptor
Technologies, LLC
Otsuka Global Insurance, Inc.
Oncomembrane, Inc.
CG Roxane, LLC
Crystal Geyser Brand Holdings, LLC
Galenea Corp.
Taiho Pharma U.S.A., Inc.
Otsuka America Foods, Inc.
American Peptide Company, Inc.
Graceland Fruit, Inc.
U.K.:
Otsuka Pharmaceutical Europe Ltd.
Otsuka Pharmaceuticals (U.K.) Ltd.
Taiho Pharma Europe, Limited
Sweden:
Otsuka Pharma Scandinavia AB
Germany:
Advanced Biochemical
Compounds GmbH
Cambridge Isotope Laboratories
(Europe) GmbH
Euriso-Top GmbH
Otsuka Pharma GmbH
Otsuka Frankfurt
Research Institute GmbH
Otsuka Novel Products GmbH
Canada:
Otsuka Canada Pharmaceutical, Inc.
2768691 Canada, Inc.
France:
Nardobel SAS
Nutrition & Sante SAS
Nutrition & Nature SAS
Laboratoires Dietetique et Sante SAS
Euriso-Top SAS
Valpiform Compiegne SNC
Valpiform SAS
Otsuka Pharmaceutical France SAS
ALMA S. A.
Kisco International SAS
Brazil:
Otsuka Chemical do Brasil Ltda.
Belgium:
Nutrition & Sante Benelux S. A.
Switzerland:
Nutrinat AG
Otsuka S. A.
Italy:
Nutrition & Sante Italia SpA
Otsuka Pharmaceutical Italy S.r.l.
Era Endoscopy S.r.l.
Spain:
Otsuka Pharmaceutical, S. A.
Nutrition & Sante Iberia SL
Hebron S. A.
Trocellen Iberica S. A.
Czech:
Interpharma Praha, a.s.
as of March 2013
52 53
Turkey:
Abdi Ibrahim Otsuka Pharmaceutical
Company
Editor’s Note
China:
Sichuan Otsuka Pharmaceutical Co., Ltd.
Guangdong Otsuka Pharmaceutical Co., Ltd.
Otsuka (China) Investment Co., Ltd.
Zhejiang Otsuka Pharmaceutical Co., Ltd.
Tianjin Otsuka Beverage Co., Ltd.
Otsuka Pharmaceutical (H.K.) Ltd.
Hangzhou Linan Kangle Pharmaceutical Co., Ltd.
Otsuka Beijing Research Institute
Otsuka Shanghai Research Institute
Otsuka Electronics Shanghai Co., Ltd.
Otsuka Sims (Guangdong) Beverage Co., Ltd.
Otsuka Electronics (Suzhou) Co., Ltd.
China Otsuka Pharmaceutical Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd.
VV Food & Beverage Co., Ltd.
Xiamen United Medical Instruments Co., Ltd.
Giant Harvest, Ltd.
Microport Scientific Corporation
Taiho Pharmaceutical of Beijing Co., Ltd.
Suzhou Otsuka Pharmaceutical Co., Ltd.
Leshan Otsuka Techno Co., Ltd.
Nanjing Otsuka Techbond Techno Co., Ltd.
Shanghai Otsuka Foods Co., Ltd.
Dalian Otsuka Furniture Co., Ltd.
Zhangjiagang Otsuka Chemical Co., Ltd.
Otsuka (Shanghai) Foods Safety Research &
Development Co., Ltd.
MOC Chemicals Trading (Shanghai) Co., Ltd.
Otsuka Material Science & Technology
(Shanghai) Co., Ltd.
Chongqing Otsuka Huayi Chemical Co., Ltd.
Achieva Medical Limited
South Korea:
Korea Otsuka Pharmaceutical Co., Ltd.
Korea OIAA Co., Ltd.
Otsuka Electronics Korea Co., Ltd.
Dong-A Otsuka Co., Ltd.
KOC Co.,Ltd.
Taiwan:
Taiwan Otsuka Pharmaceutical Co., Ltd.
Otsuka Tech Electronics Co., Ltd.
King Car Otsuka Co., Ltd.
India:
Otsuka Chemical (India) Private Limited
Indonesia:
P.T. Otsuka Jaya Indah
P.T. Merapi Utama Pharma
P.T. Amerta Indah Otsuka
P.T. Widatra Bhakti
P.T. Otsuka Indonesia
P.T. Lautan Otsuka Chemical
Thailand:
Otsuka Saha Asia Research Co., Ltd.
Thai Otsuka Pharmaceutical Co., Ltd.
Philippines:
Otsuka (Philippines) Pharmaceutical, Inc.
Pakistan:
Otsuka Pakistan Ltd.
Vietnam:
Otsuka OPV Joint Stock Company
Otsuka Thang Nutrition Co., Ltd.
Egypt:
Egypt Otsuka Pharmaceutical Co., S.A.E.
Otsuka Trading Africa Co., S.A.E.
Otsuka Import Export, LLC
Singapore:
Taiho Pharma Singapore Pte. Ltd.
New Zealand:
Diatranz Otsuka Limited
Japan:
Otsuka Holdings Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Factory, Inc.
Taiho Pharmaceutical Co., Ltd.
Otsuka Warehouse Co., Ltd.
Otsuka Chemical Co., Ltd.
Otsuka Medical Devices Co., Ltd.
Otsuka Electronics Co., Ltd.
EN Otsuka Pharmaceutical Co., Ltd.
Naruto Cruise Service Co., Ltd.
Heartful Kawauchi Co., Ltd.
Otsuka Ridge Co., Ltd.
Nippon Pharmaceutical Chemicals
Co., Ltd.
Chuo Electronic Measurement Co., Ltd.
Earth Chemical Co., Ltd.
Earth Environmental Service Co., Ltd.
Kitasato-Otsuka Biomedical Assay
Laboratories Co., Ltd.
Ribomic, Inc.
Tokushima Vortis Co., Ltd.
Bean Stalk Snow Co., Ltd.
Okayama Taiho Pharmaceutical Co., Ltd.
Nichiban Co., Ltd.
Otsuka Techno Corporation
J.O.Pharma Co., Ltd.
Otsuka Naruto Development Co., Ltd.
Naruto Salt Mfg. Co., Ltd.
Tokushima Air Terminal Building
Co., Ltd.
Otsuka Packaging Industries Co., Ltd.
Dairin Integrated Transportation
Co., Ltd.
HAIESU Service Co., Ltd.
Big Bell Co., Ltd.
Awa Union transportation Co., Ltd.
Otsuka Foods Co., Ltd.
Otsuka Chilled Foods Co., Ltd.
Otsuka-MGC Chemical Company, Inc.
Otsuka Turftech Co., Ltd.
ILS, Inc.
Otsuka Furniture Manufacturing
and Sales Co., Ltd.
Agri Best Co., Ltd.
Otsuka Ohmi Ceramics Co., Ltd.
Marukita Furniture Center (tentative)
Yoshino Farm (tentative)
NEOS Corporation
Earth Biochemical Co., Ltd.
JIMRO Co., Ltd.
KiSCO Co., Ltd.
It has been a challenge to produce a corporate brochure for a constantly changing, dynamic organization like Otsuka Pharmaceutical. It was almost like trying to describe a
living thing, and we learned a great deal in
the process.
First, we came to appreciate how diffi cult
it is to select the most important information, while still adhering to the schedule
of an annual publication. Meanwhile, we
had to embrace the challenge of conveying a proper understanding of business
and product developments that have been
underway for many years. Finally, we saw
clearly how even slight differences in the
nuance conveyed by tone of voice, photos,
and illustrations can completely alter what
is conveyed. In all of these ways, we felt
the signifi cance of this corporate brochure
and rediscovered how important it is to pay
very close attention to every detail.
What stood out more than anything else
was that Otsuka Pharmaceutical is truly sustained by and grows because of its people.
We would like to take this opportunity to
express our heartfelt thanks to everyone in
and outside Japan who provided guidance
during the process of creating this corporate brochure.
Public Relations Department:
Hidehiko Hirabayashi
Keiko Tashiro
Reiko Nakajima
Mai Yamada
Jeffrey Gilbert
Akiko Ryu Innes-Taylor,
Head of Public Relations
Published by:
Public Relations Department,
Otsuka Pharmaceutical Co., Ltd.
Shinagawa Grand Central Tower
2-16-4, Konan, Minato-ku,
Tokyo 108-8242, Japan
Tel: +81-3-6717-1400
www.otsuka.co.jp (Japanese)
www.otsuka.co.jp/en (English)
Design:
Helmut Schmid Design
Illustration:
Jean-Paul Buquet
Production:
Nippon International
Agency
In 1971 a camphor tree seedling was
planted in front of the newly-established
Otsuka Pharmaceutical Drug Research
Institute. Across the subsequent
40-plus years, the tree has grown into
an imposing presence and for the
researchers at Otsuka it is the perfect
metaphor and inspiration to be creative
always and take on the most daunting
challenges.
The words ‘Otsuka-people creating new
products for better health worldwide,’
which are carved in a stone monument
at the base of the commemorative
tree were first penned as the motto
for the research department and later
became the corporate philosophy
for the Otsuka Group.
1311E